Drugs facing NCE-1 in 2023
1. Accrufer patent expiration
ACCRUFER's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9802973 | SHIELD TX | Crystalline forms of ferric maltol |
Oct, 2035
(10 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9248148 | SHIELD TX | Mono (iron hydroxypyrone) and combination (iron hydroxypyrone and GI inflammation inhibiting agents) compositions for anaemia or H. pylori infections |
Mar, 2031
(5 years from now) | |
| US10179120 | SHIELD TX | Dosage regimen of ferric trimaltol |
Jan, 2035
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jul 25, 2024 |
Drugs and Companies using FERRIC MALTOL ingredient
NCE-1 date: 26 July, 2023
Market Authorisation Date: 25 July, 2019
Treatment: Method of treating iron deficiency
Dosage: CAPSULE
More Information on Dosage
ACCRUFER family patents
2. Aklief patent expiration
AKLIEF's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7807708 | GALDERMA LABS LP | Ligands that modulate RAR receptors and pharmaceutical/cosmetic compositions comprised thereof |
Jul, 2031
(6 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8227507 | GALDERMA LABS LP | Ligands that modulate RAR receptors |
Dec, 2025
(6 months from now) | |
| US8470871 | GALDERMA LABS LP | Ligands that modulate RAR receptors |
Dec, 2025
(6 months from now) | |
| US9498465 | GALDERMA LABS LP | Topical compositions in the form of a gel containing a particular solubilized retinoid |
May, 2033
(8 years from now) | |
| US9084778 | GALDERMA LABS LP | Topical compositions containing a retinoid of the oil-in-water emulsion type |
May, 2033
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Oct 04, 2024 |
Drugs and Companies using TRIFAROTENE ingredient
NCE-1 date: 05 October, 2023
Market Authorisation Date: 04 October, 2019
Treatment: Topical treatment of acne vulgaris; Method of activating rargamma receptor; Treatment of acne vulgaris
Dosage: CREAM
More Information on Dosage
AKLIEF family patents
3. Aubagio patent
expiration
AUBAGIO's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5459163 | SANOFI AVENTIS US | Medicament to combat autoimmune diseases |
Oct, 2012
(12 years ago) | |
| US5679709 | SANOFI AVENTIS US | Medicaments to combat autoimmune diseases |
Oct, 2014
(10 years ago) | |
| US6794410 | SANOFI AVENTIS US | Use of (Z)-2-cyano-3-hydroxy-but-2-enoic acid-(4′-trifluoromethylphenyl)-amide for treating multiple sclerosis |
Sep, 2026
(1 year, 3 months from now) | |
|
US6794410 (Pediatric) | SANOFI AVENTIS US | Use of (Z)-2-cyano-3-hydroxy-but-2-enoic acid-(4′-trifluoromethylphenyl)-amide for treating multiple sclerosis |
Mar, 2027
(1 year, 9 months from now) | |
| US8802735 | SANOFI AVENTIS US | (Z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluormethylphenyl)-amide tablet formulations with improved stability |
Sep, 2030
(5 years from now) | |
|
US8802735 (Pediatric) | SANOFI AVENTIS US | (Z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluormethylphenyl)-amide tablet formulations with improved stability |
Mar, 2031
(5 years from now) | |
| US9186346 | SANOFI AVENTIS US | Methods for reducing the risk of an adverse teriflunomide and rosuvastatin interaction in multiple sclerosis patients |
Feb, 2034
(8 years from now) | |
|
US9186346 (Pediatric) | SANOFI AVENTIS US | Methods for reducing the risk of an adverse teriflunomide and rosuvastatin interaction in multiple sclerosis patients |
Aug, 2034
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Sep 12, 2017 |
| M(M-61) | Apr 30, 2024 |
| Pediatric Exclusivity(PED) | Oct 30, 2024 |
Drugs and Companies using TERIFLUNOMIDE ingredient
NCE-1 date: 31 October, 2023
Market Authorisation Date: 12 September, 2012
Treatment: Treatment of patients with relapsing forms of multiple sclerosis; Treatment of patients with relapsing forms of multiple sclerosis while managing the risk of teriflunomide and rosuvastatin interaction...
Dosage: TABLET
How can I launch a generic of AUBAGIO before it's drug patent expiration?
More Information on Dosage
AUBAGIO family patents
4. Austedo patent expiration
AUSTEDO IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8524733 | TEVA BRANDED PHARM | Benzoquinoline inhibitors of vesicular monoamine transporter 2 |
Apr, 2031
(5 years from now) | |
| US9550780 | TEVA BRANDED PHARM | Formulations pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2 |
Sep, 2033
(8 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US8524733 (Pediatric) | TEVA BRANDED PHARM | Benzoquinoline inhibitors of vesicular monoamine transporter 2 |
Oct, 2031
(6 years from now) | |
| US9814708 | TEVA BRANDED PHARM | Formulations and pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2 |
Sep, 2033
(8 years from now) | |
| US9233959 | TEVA BRANDED PHARM | Formulations and pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2 |
Sep, 2033
(8 years from now) | |
| US9296739 | TEVA BRANDED PHARM | Formulations and pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2 |
Sep, 2033
(8 years from now) | |
| US11666566 | TEVA BRANDED PHARM | Formulations and pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2 |
Sep, 2033
(8 years from now) | |
|
US9296739 (Pediatric) | TEVA BRANDED PHARM | Formulations and pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2 |
Mar, 2034
(8 years from now) | |
|
US9814708 (Pediatric) | TEVA BRANDED PHARM | Formulations and pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2 |
Mar, 2034
(8 years from now) | |
|
US9550780 (Pediatric) | TEVA BRANDED PHARM | Formulations pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2 |
Mar, 2034
(8 years from now) | |
|
US11666566 (Pediatric) | TEVA BRANDED PHARM | Formulations and pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2 |
Mar, 2034
(8 years from now) | |
|
US9233959 (Pediatric) | TEVA BRANDED PHARM | Formulations and pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2 |
Mar, 2034
(8 years from now) | |
| US11648244 | TEVA BRANDED PHARM | Methods for the treatment of abnormal involuntary movement disorders |
Mar, 2036
(10 years from now) | |
| US10959996 | TEVA BRANDED PHARM | Methods for the treatment of abnormal involuntary movement disorders |
Mar, 2036
(10 years from now) | |
| US11357772 | TEVA BRANDED PHARM | Methods for the treatment of abnormal involuntary movement disorders |
Mar, 2036
(10 years from now) | |
| US12016858 | TEVA BRANDED PHARM | Methods for the treatment of abnormal involuntary movement disorders |
Mar, 2036
(10 years from now) | |
| US11564917 | TEVA BRANDED PHARM | Methods for the treatment of abnormal involuntary movement disorders |
Mar, 2036
(10 years from now) | |
| US11446291 | TEVA BRANDED PHARM | Methods for the treatment of abnormal involuntary movement disorders |
Mar, 2036
(10 years from now) | |
|
US11357772 (Pediatric) | TEVA BRANDED PHARM | Methods for the treatment of abnormal involuntary movement disorders |
Sep, 2036
(11 years from now) | |
|
US10959996 (Pediatric) | TEVA BRANDED PHARM | Methods for the treatment of abnormal involuntary movement disorders |
Sep, 2036
(11 years from now) | |
|
US11648244 (Pediatric) | TEVA BRANDED PHARM | Methods for the treatment of abnormal involuntary movement disorders |
Sep, 2036
(11 years from now) | |
|
US11446291 (Pediatric) | TEVA BRANDED PHARM | Methods for the treatment of abnormal involuntary movement disorders |
Sep, 2036
(11 years from now) | |
|
US11564917 (Pediatric) | TEVA BRANDED PHARM | Methods for the treatment of abnormal involuntary movement disorders |
Sep, 2036
(11 years from now) | |
|
US12016858 (Pediatric) | TEVA BRANDED PHARM | Methods for the treatment of abnormal involuntary movement disorders |
Sep, 2036
(11 years from now) | |
| US11179386 | TEVA BRANDED PHARM | Analogs of deutetrabenazine, their preparation and use |
Mar, 2038
(12 years from now) | |
| US11813232 | TEVA BRANDED PHARM | Analogs of deutetrabenazine, their preparation and use |
Mar, 2038
(12 years from now) | |
|
US11179386 (Pediatric) | TEVA BRANDED PHARM | Analogs of deutetrabenazine, their preparation and use |
Sep, 2038
(13 years from now) | |
|
US11813232 (Pediatric) | TEVA BRANDED PHARM | Analogs of deutetrabenazine, their preparation and use |
Sep, 2038
(13 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-751) | Aug 30, 2020 |
| New Chemical Entity Exclusivity(NCE) | Apr 03, 2022 |
| Orphan Drug Exclusivity(ODE) | Apr 03, 2024 |
| Orphan Drug Exclusivity(ODE-134) | Apr 03, 2024 |
| M(M-54) | Jun 24, 2024 |
| Pediatric Exclusivity(PED) | Dec 24, 2024 |
Drugs and Companies using DEUTETRABENAZINE ingredient
NCE-1 date: 25 December, 2023
Market Authorisation Date: 03 April, 2017
Treatment: Treatment of tardive dyskinesia; A method of treating huntington's chorea
Dosage: TABLET
How can I launch a generic of AUSTEDO before it's drug patent expiration?
More Information on Dosage
AUSTEDO family patents
5. Balversa patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8895601 | JANSSEN BIOTECH | Pyrazolyl quinoxaline kinase inhibitors |
Apr, 2033
(7 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9464071 | JANSSEN BIOTECH | Pyrazolyl quinoxaline kinase inhibitors |
Apr, 2031
(5 years from now) | |
| US9902714 | JANSSEN BIOTECH | Quinoxaline derivatives useful as FGFR kinase modulators |
Mar, 2035
(9 years from now) | |
| US12037644 | JANSSEN BIOTECH | Use of FGFR mutant gene panels in identifying cancer patients that will be responsive to treatment with an FGFR inhibitor |
Oct, 2035
(10 years from now) | |
| US11684620 | JANSSEN BIOTECH | Pharmaceutical compositions comprising N-(3,5-dimethoxyphenyl)-N′-(1-methylethyl)-N-[3-(1-methyl-1H-pyrazol-4-yl)quinoxalin-6-yl]ethane-1,2-diamine |
Feb, 2036
(10 years from now) | |
| US10898482 | JANSSEN BIOTECH | Pharmaceutical compositions comprising N-(3,5-dimethoxyphenyl)-N'-1 methylethyl)-N-[3-(1-methyl-1H-pyrazol-4-yl)quinoxalin-6-yl]ethane-1,2-diamine |
Feb, 2036
(10 years from now) | |
| US10478494 | JANSSEN BIOTECH | FGFR/PD-1 combination therapy for the treatment of cancer |
Aug, 2036
(11 years from now) | |
| US11077106 | JANSSEN BIOTECH | Cancer treatment |
Feb, 2038
(12 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Apr 12, 2024 |
| New Indication(I-930) | Jan 19, 2027 |
Drugs and Companies using ERDAFITINIB ingredient
NCE-1 date: 13 April, 2023
Market Authorisation Date: 12 April, 2019
Treatment: Treatment of adults with locally advanced or metastatic urothelial carcinoma with susceptible fgfr3 genetic alterations whose disease has progressed on or after at least one line of prior systemic the...
Dosage: TABLET
How can I launch a generic of BALVERSA before it's drug patent expiration?
More Information on Dosage
BALVERSA family patents
6. Brukinsa patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9447106 | BEIGENE | Substituted pyrazolo[1,5-a]pyrimidines as bruton's tyrosine kinase modulators |
Apr, 2034
(8 years from now) | |
| US10927117 | BEIGENE | Crystalline form of (S)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetra-hydropyrazolo[1,5-a]pyrimidine-3-carboxamide, preparation, and uses thereof |
Aug, 2037
(12 years from now) | |
| US11851437 | BEIGENE | Crystalline form of (S)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetra-hydropyrazolo[1,5-a]pyrimidine-3-carboxamide, preparation, and uses thereof |
Aug, 2037
(12 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11142528 | BEIGENE | Substituted pyrazolo[1,5-a]pyrimidines as Bruton's tyrosine kinase modulators |
Apr, 2034
(8 years from now) | |
| US10570139 | BEIGENE | Substituted pyrazolo[1,5-a]pyrimidines as Bruton's tyrosine kinase modulators |
Apr, 2034
(8 years from now) | |
| US11591340 | BEIGENE | Crystalline form of (S)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetra- hydropyrazolo[1,5-a]pyrimidine-3-carboxamide, preparation, and uses thereof |
Aug, 2037
(12 years from now) | |
| US11970500 | BEIGENE | Crystalline form of (s)-7-(1-acryloylpiperidin-4-yl)- 2-(4-phenoxyphenyl)-4,5,6,7-tetra- hydropyrazolo[1,5-a]pyrimidine-3-carboxamide, preparation, and uses thereof |
Aug, 2037
(12 years from now) | |
| US11884674 | BEIGENE | Crystalline form of (S)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetra- hydropyrazolo[1,5-a]pyrimidine-3-carboxamide, preparation, and uses thereof |
Aug, 2037
(12 years from now) | |
| US11701357 | BEIGENE | Treatment of B cell cancers using a combination comprising Btk inhibitors |
Jun, 2039
(14 years from now) | |
| US11786531 | BEIGENE | Methods of treating B-cell proliferative disorder |
Jan, 2043
(17 years from now) | |
| US11911386 | BEIGENE | Methods of treating B-cell proliferative disorder |
Jan, 2043
(17 years from now) | |
| US11896596 | BEIGENE | Methods of treating B-cell proliferative disorder |
Jan, 2043
(17 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-871) | Aug 31, 2024 |
| New Indication(I-874) | Sep 14, 2024 |
| New Chemical Entity Exclusivity(NCE) | Nov 14, 2024 |
| New Indication(I-817) | Jan 19, 2026 |
| Orphan Drug Exclusivity(ODE-276) | Nov 14, 2026 |
| New Indication(I-936) | Mar 07, 2027 |
| Orphan Drug Exclusivity(ODE-371) | Aug 31, 2028 |
| Orphan Drug Exclusivity(ODE-370) | Sep 14, 2028 |
| Orphan Drug Exclusivity(ODE-274) | Jan 19, 2030 |
| Orphan Drug Exclusivity(ODE-467) | Mar 07, 2031 |
Drugs and Companies using ZANUBRUTINIB ingredient
NCE-1 date: 15 November, 2023
Market Authorisation Date: 14 November, 2019
Treatment: Treatment of adult patients with small lymphocytic lymphoma; Treatment of adult patients with mantle cell lymphoma who have received at least one prior therapy; Treatment of adult patients with chroni...
Dosage: CAPSULE
More Information on Dosage
BRUKINSA family patents
7. Caplyta patent expiration
CAPLYTA's oppositions filed in EPO
Can you believe CAPLYTA received compensation for the extended wait time during the regulatory approval process?
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7183282 | INTRA-CELLULAR | Substituted heterocycle fused γ-carbolines |
Jun, 2020
(4 years ago) | |
| USRE39680 | INTRA-CELLULAR | Substituted heterocycle fused gamma-carbolines |
Jun, 2020
(4 years ago) | |
| USRE48825 | INTRA-CELLULAR | 4-((6bR,10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H-pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalin-8(7H)-yl)-1-(4-fluorophenyl)-1-butanone toluenesulfonic acid salt crystal forms |
Mar, 2029
(3 years from now) | |
| US9586960 | INTRA-CELLULAR | 4-((6bR,10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H-pyrido[3′,4′:4,5]pyrrolo[1,2,3-de] quinoxalin-8(7H)-yl)-1-(4-fluorophenyl)-1-butanone toluenesulfonic acid salt crystal forms |
Mar, 2029
(3 years from now) | |
| US8648077 | INTRA-CELLULAR | 4-((6bR,10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H-pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalin-8(7H)-yl)-1-(4-fluorophenyl)-1-butanone toluenesulfonic acid addition salt and salt crystals |
Dec, 2029
(4 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10464938 | INTRA-CELLULAR | Pharmaceutical compositions comprising ((6bR,10aS)-1-(4-fluorophenyl)-4-(3-methyl-2,3,6b,9,10,10a-hexahydro-1H-pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalin-8(7H)-yl)butan-1-one or pharmaceutically acceptable salts thereof |
Mar, 2028
(2 years from now) | |
| US9199995 | INTRA-CELLULAR | 4-((6bR,10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H-pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalin-8(7H)-yl)-1-(4-fluorophenyl)-1-butanone toluenesulfonic acid addition salt and salt crystals |
Mar, 2029
(3 years from now) | |
| US10117867 | INTRA-CELLULAR | Methods and compositions for sleep disorders and other disorders |
May, 2029
(3 years from now) | |
| US9616061 | INTRA-CELLULAR | Methods and compositions for sleep disorders and other disorders |
May, 2029
(3 years from now) | |
| US9168258 | INTRA-CELLULAR | Methods and compositions for sleep disorders and other disorders |
May, 2029
(3 years from now) | |
| US8598119 | INTRA-CELLULAR | Methods and compositions for sleep disorders and other disorders |
Dec, 2029
(4 years from now) | |
| USRE48839 | INTRA-CELLULAR | Methods and compositions for sleep disorders and other disorders |
Aug, 2033
(8 years from now) | |
| US11026951 | INTRA-CELLULAR | Methods of treating bipolar disorder |
Dec, 2034
(9 years from now) | |
| US9956227 | INTRA-CELLULAR | Method for the treatment of residual symptoms of schizophrenia |
Dec, 2034
(9 years from now) | |
| US10960009 | INTRA-CELLULAR | Methods of treating schizophrenia and depression |
Dec, 2034
(9 years from now) | |
| US12070459 | INTRA-CELLULAR | Pharmaceutical capsule compositions comprising lumateperone mono-tosylate |
Aug, 2039
(14 years from now) | |
| US10695345 | INTRA-CELLULAR | Pharmaceutical capsule compositions comprising lumateperone mono-tosylate |
Aug, 2039
(14 years from now) | |
| US11806348 | INTRA-CELLULAR | Methods of treatment using pharmaceutical capsule compositions comprising lumateperone mono-tosylate |
Aug, 2039
(14 years from now) | |
| US11052084 | INTRA-CELLULAR | Pharmaceutical capsule compositions comprising lumateperone mono-tosylate |
Aug, 2039
(14 years from now) | |
| US11690842 | INTRA-CELLULAR | Pharmaceutical capsule compositions comprising lumateperone mono-tosylate |
Aug, 2039
(14 years from now) | |
| US12128043 | INTRA-CELLULAR | Pharmaceutical capsules comprising lumateperone mono-tosylate |
Aug, 2039
(14 years from now) | |
| US11980617 | INTRA-CELLULAR | Methods of treating acute depression and/or acute anxiety |
Oct, 2039
(14 years from now) | |
| US12090155 | INTRA-CELLULAR | Methods |
Jul, 2040
(15 years from now) | |
| US11753419 | INTRA-CELLULAR | 4-((6bR,10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H-pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalin-8(7H)-yl)-1-(4-((6bR,10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H-pyrido[3′4′:4,5]pyrrolo[1,2,3-de]quinoxalin-8(7H)-yl)phenyl)butan-1-one for treating conditions of the central nervous system and cardiac disorders |
Dec, 2040
(15 years from now) | |
| US12122792 | INTRA-CELLULAR | Pharmaceutical compositions comprising 4-((6bR,10aS)-3-methyl2,3,6b,9,10,10a-hexahydro-1H-pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalin8(7H)-yl)-1-(4-((6bR,10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H-pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalin-8(7H)-yl)phenyl)butan-1-one for treating conditions of the central nervous system and cardiac disorders |
Dec, 2040
(15 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-882) | Dec 17, 2024 |
| New Chemical Entity Exclusivity(NCE) | Dec 20, 2024 |
Drugs and Companies using LUMATEPERONE TOSYLATE ingredient
NCE-1 date: 21 December, 2023
Market Authorisation Date: 22 April, 2022
Treatment: Modulation of 5-hydroxytryptamine 2 receptor activity in schizophrenia; Treatment of bipolar depression; Treatment of schizophrenia; Treatment of bipolar disorder i, bipolar disorder ii, or bipolar de...
Dosage: CAPSULE
More Information on Dosage
CAPLYTA family patents
8. Dalvance patent expiration
DALVANCE's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8143212 | ABBVIE | Dalbavancin compositions for treatment of bacterial infections |
Nov, 2023
(1 year, 6 months ago) | |
| US7115564 | ABBVIE | Stable pharmaceutical compositions of dalbavancin and methods of administration |
Nov, 2023
(1 year, 6 months ago) | |
| US7119061 | ABBVIE | Dalbavancin compositions for treatment of bacterial infections |
Nov, 2023
(1 year, 6 months ago) | |
| US6900175 | ABBVIE | Methods of administering dalbavancin for treatment of bacterial infections |
May, 2028
(2 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Dosing Schedule(D-154) | Jan 20, 2019 |
| New Chemical Entity Exclusivity(NCE) | May 23, 2019 |
| Generating Antibiotic Incentives Now(GAIN) | May 23, 2024 |
| New Patient Population(NPP) | Jul 22, 2024 |
Drugs and Companies using DALBAVANCIN HYDROCHLORIDE ingredient
NCE-1 date: 24 May, 2023
Market Authorisation Date: 23 May, 2014
Treatment: Treatment of bacterial infections using a two-dose regimen of dalbavancin.; Treatment of acute bacterial skin and skin structure infections (absssi) in adult and pediatric patients using a two-dose re...
Dosage: POWDER
More Information on Dosage
DALVANCE family patents
9. Exem Foam Kit patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9034300 | GISKIT | Composition and method for medical imaging of body cavities |
Oct, 2030
(5 years from now) | |
| US9259494 | GISKIT | Composition and method for medical imaging of body cavities |
May, 2035
(9 years from now) | |
| US9849199 | GISKIT | Composition and method for medical imaging of body cavities |
Feb, 2036
(10 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Nov 07, 2024 |
Drugs and Companies using AIR POLYMER-TYPE A ingredient
NCE-1 date: 08 November, 2023
Market Authorisation Date: 07 November, 2019
Treatment: Use in sonohysterosalpinography to assess fallopian tube patency
Dosage: FOAM
More Information on Dosage
EXEM FOAM KIT family patents
10. Givlaari patent expiration
GIVLAARI's oppositions filed in EPO
GIVLAARI IPR and PTAB Proceedings
Can you believe GIVLAARI received compensation for the extended wait time during the regulatory approval process?
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8546143 | ALNYLAM PHARMS INC | Compositions and methods for inhibiting expression of a target gene |
Jan, 2022
(3 years ago) | |
| US9708610 | ALNYLAM PHARMS INC | Compositions comprising alternating 2′-modified nucleosides for use in gene modulation |
Jan, 2024
(1 year, 4 months ago) | |
| US10273477 | ALNYLAM PHARMS INC | Therapeutic compositions |
Mar, 2024
(1 year, 2 months ago) | |
| US9708615 | ALNYLAM PHARMS INC | Therapeutic compositions |
Mar, 2024
(1 year, 2 months ago) | |
| US11530408 | ALNYLAM PHARMS INC | Therapeutic compositions |
May, 2024
(1 year, 10 days ago) | |
| US9150605 | ALNYLAM PHARMS INC | Compositions comprising alternating 2′-modified nucleosides for use in gene modulation |
Aug, 2025
(2 months from now) | |
| US10131907 | ALNYLAM PHARMS INC | Glycoconjugates of RNA interference agents |
Aug, 2028
(3 years from now) | |
| US8828956 | ALNYLAM PHARMS INC | Carbohydrate conjugates as delivery agents for oligonucleotides |
Dec, 2028
(3 years from now) | |
| US8106022 | ALNYLAM PHARMS INC | Carbohydrate conjugates as delivery agents for oligonucleotides |
Dec, 2029
(4 years from now) | |
| US10125364 | ALNYLAM PHARMS INC | Compositions and methods for inhibiting expression of the ALAS1 gene |
Mar, 2033
(7 years from now) | |
| US9133461 | ALNYLAM PHARMS INC | Compositions and methods for inhibiting expression of the ALAS1 gene |
Nov, 2033
(8 years from now) | |
| US10119143 | ALNYLAM PHARMS INC | Compositions and methods for inhibiting expression of the ALAS1 gene |
Oct, 2034
(9 years from now) | |
| US11028392 | ALNYLAM PHARMS INC | Compositions and methods for inhibiting expression of the ALAS1 gene |
Oct, 2034
(9 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9631193 | ALNYLAM PHARMS INC | Compositions and methods for inhibiting expression of the ALAS1 gene |
Mar, 2033
(7 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Nov 20, 2024 |
| Orphan Drug Exclusivity(ODE-273) | Nov 20, 2026 |
Drugs and Companies using GIVOSIRAN SODIUM ingredient
NCE-1 date: 21 November, 2023
Market Authorisation Date: 20 November, 2019
Treatment: Treatment of acute hepatic porphyria
Dosage: SOLUTION
More Information on Dosage
GIVLAARI family patents
11. Harvoni patent expiration
HARVONI's oppositions filed in EPO
HARVONI IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8334270 | GILEAD SCIENCES INC | NA |
Mar, 2028
(2 years from now) | |
| US8580765 | GILEAD SCIENCES INC | NA |
Mar, 2028
(2 years from now) | |
| US9085573 | GILEAD SCIENCES INC | NA |
Mar, 2028
(2 years from now) | |
| US7964580 | GILEAD SCIENCES INC | NA |
Mar, 2029
(3 years from now) | |
| US8633309 | GILEAD SCIENCES INC | Nucleoside phosphoramidates |
Mar, 2029
(3 years from now) | |
| US8822430 | GILEAD SCIENCES INC | Antiviral compounds |
May, 2030
(4 years from now) | |
| US8088368 | GILEAD SCIENCES INC | Antiviral compounds |
May, 2030
(4 years from now) | |
| US9284342 | GILEAD SCIENCES INC | Nucleoside phosphoramidates |
Sep, 2030
(5 years from now) | |
| US8618076 | GILEAD SCIENCES INC | Nucleoside phosphoramidates |
Dec, 2030
(5 years from now) | |
| US10039779 | GILEAD SCIENCES INC | Combination formulation of two antiviral compounds |
Jan, 2034
(8 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8735372 | GILEAD SCIENCES INC | NA |
Mar, 2028
(2 years from now) | |
|
US8735372 (Pediatric) | GILEAD SCIENCES INC | NA |
Sep, 2028
(3 years from now) | |
|
US8334270 (Pediatric) | GILEAD SCIENCES INC | NA |
Sep, 2028
(3 years from now) | |
|
US8580765 (Pediatric) | GILEAD SCIENCES INC | NA |
Sep, 2028
(3 years from now) | |
|
US9085573 (Pediatric) | GILEAD SCIENCES INC | NA |
Sep, 2028
(3 years from now) | |
| US8889159 | GILEAD SCIENCES INC | Compositions and methods for treating hepatitis C virus |
Mar, 2029
(3 years from now) | |
|
US7964580 (Pediatric) | GILEAD SCIENCES INC | NA |
Sep, 2029
(4 years from now) | |
|
US8633309 (Pediatric) | GILEAD SCIENCES INC | Nucleoside phosphoramidates |
Sep, 2029
(4 years from now) | |
|
US8889159 (Pediatric) | GILEAD SCIENCES INC | Compositions and methods for treating hepatitis C virus |
Sep, 2029
(4 years from now) | |
| US8273341 | GILEAD SCIENCES INC | Antiviral compounds |
May, 2030
(4 years from now) | |
| US9511056 | GILEAD SCIENCES INC | Antiviral compounds |
May, 2030
(4 years from now) | |
| US8841278 | GILEAD SCIENCES INC | Antiviral compounds |
May, 2030
(4 years from now) | |
|
US9511056 (Pediatric) | GILEAD SCIENCES INC | Antiviral compounds |
Nov, 2030
(5 years from now) | |
|
US8822430 (Pediatric) | GILEAD SCIENCES INC | Antiviral compounds |
Nov, 2030
(5 years from now) | |
|
US8088368 (Pediatric) | GILEAD SCIENCES INC | Antiviral compounds |
Nov, 2030
(5 years from now) | |
|
US8273341 (Pediatric) | GILEAD SCIENCES INC | Antiviral compounds |
Nov, 2030
(5 years from now) | |
|
US8841278 (Pediatric) | GILEAD SCIENCES INC | Antiviral compounds |
Nov, 2030
(5 years from now) | |
|
US9284342 (Pediatric) | GILEAD SCIENCES INC | Nucleoside phosphoramidates |
Mar, 2031
(5 years from now) | |
|
US8618076 (Pediatric) | GILEAD SCIENCES INC | Nucleoside phosphoramidates |
Jun, 2031
(6 years from now) | |
| US10456414 | GILEAD SCIENCES INC | Methods for treating HCV |
Sep, 2032
(7 years from now) | |
| US9393256 | GILEAD SCIENCES INC | Methods for treating HCV |
Sep, 2032
(7 years from now) | |
|
US9393256 (Pediatric) | GILEAD SCIENCES INC | Methods for treating HCV |
Mar, 2033
(7 years from now) | |
|
US10039779 (Pediatric) | GILEAD SCIENCES INC | Combination formulation of two antiviral compounds |
Jul, 2034
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Dosing Schedule(D-153) | Nov 12, 2018 |
| New Indication(I-718) | Nov 12, 2018 |
| New Indication(I-719) | Nov 12, 2018 |
| New Indication(I-720) | Nov 12, 2018 |
| New Dosing Schedule(D-158) | Feb 12, 2019 |
| New Dosing Schedule(D-159) | Feb 12, 2019 |
| New Dosing Schedule(D-160) | Feb 12, 2019 |
| New Chemical Entity Exclusivity(NCE) | Oct 10, 2019 |
| New Patient Population(NPP) | Apr 07, 2020 |
| New Dosing Schedule(D-177) | Nov 15, 2022 |
| Orphan Drug Exclusivity(ODE) | Apr 07, 2024 |
| Orphan Drug Exclusivity(ODE-136) | Apr 07, 2024 |
| Pediatric Exclusivity(PED) | Oct 07, 2024 |
| ODE*(ODE*) | Aug 28, 2026 |
| Orphan Drug Exclusivity(ODE-262) | Aug 28, 2026 |
| Orphan Drug Exclusivity(ODE-263) | Aug 28, 2026 |
| Orphan Drug Exclusivity(ODE-264) | Aug 28, 2026 |
Drugs and Companies using LEDIPASVIR; SOFOSBUVIR ingredient
NCE-1 date: 08 October, 2023
Market Authorisation Date: 28 August, 2019
Treatment: For the treatment of hepatitis c
Dosage: TABLET
More Information on Dosage
HARVONI family patents
12. Ibsrela patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US12016856 | ARDELYX INC | Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders |
Dec, 2029
(4 years from now) | |
| US8969377 | ARDELYX INC | Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders |
Dec, 2029
(4 years from now) | |
| US8541448 | ARDELYX INC | Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders |
Aug, 2033
(8 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9408840 | ARDELYX INC | Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorder |
Dec, 2029
(4 years from now) | |
| US9006281 | ARDELYX INC | Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders |
May, 2030
(4 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Sep 12, 2024 |
Drugs and Companies using TENAPANOR HYDROCHLORIDE ingredient
NCE-1 date: 13 September, 2023
Market Authorisation Date: 12 September, 2019
Treatment: Method of treating irritable bowel syndrome with constipation by administering tenapanor
Dosage: TABLET
More Information on Dosage
IBSRELA family patents
13. Inrebic patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7825246 | BRISTOL-MYERS | Bi-aryl meta-pyrimidine inhibitors of kinases |
Dec, 2026
(1 year, 6 months from now) | |
| US7528143 | BRISTOL-MYERS | Bi-aryl meta-pyrimidine inhibitors of kinases |
Nov, 2031
(6 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8138199 | BRISTOL-MYERS | Use of bi-aryl meta-pyrimidine inhibitors of kinases |
Jun, 2028
(3 years from now) | |
| US10391094 | BRISTOL-MYERS | Compositions and methods for treating myelofibrosis |
Jun, 2032
(7 years from now) | |
| US11400092 | BRISTOL-MYERS | Methods of treating myeloproliferative disorders |
Sep, 2039
(14 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Aug 16, 2024 |
| Orphan Drug Exclusivity(ODE-259) | Aug 16, 2026 |
Drugs and Companies using FEDRATINIB HYDROCHLORIDE ingredient
NCE-1 date: 17 August, 2023
Market Authorisation Date: 16 August, 2019
Treatment: Treatment of adult patients with intermediate-2 or high-risk primary or secondary myelofibrosis; Treating adult patients with intermediate-2 or high-risk primary or secondary myelofibrosis, monitoring...
Dosage: CAPSULE
More Information on Dosage
INREBIC family patents
14. Janumet patent expiration
JANUMET's oppositions filed in EPO
JANUMET IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7326708 | MSD SUB MERCK | Phosphoric acid salt of a dipeptidyl peptidase-IV inhibitor |
Nov, 2026
(1 year, 5 months from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6303661 | MSD SUB MERCK | Use of dipeptidyl peptidase IV effectors for lowering the blood glucose level in mammals |
Apr, 2017
(8 years ago) | |
| US6890898 | MSD SUB MERCK | Method of regulating glucose metabolism, and reagents related thereto |
Feb, 2019
(6 years ago) | |
| US7078381 | MSD SUB MERCK | Method of regulating glucose metabolism, and reagents related thereto |
Feb, 2019
(6 years ago) | |
| US7459428 | MSD SUB MERCK | Method of regulating glucose metabolism, and reagents related thereto |
Feb, 2019
(6 years ago) | |
| US6699871 | MSD SUB MERCK | Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes |
Jul, 2022
(2 years ago) | |
| US7125873 | MSD SUB MERCK | Beta-amino tetrahydroimidazo (1, 2-a) pyrazines and tetrahydrotrioazolo (4, 3-a) pyrazines as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes |
Jul, 2022
(2 years ago) | |
|
US6699871 (Pediatric) | MSD SUB MERCK | Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes |
Jan, 2023
(2 years ago) | |
|
US7125873 (Pediatric) | MSD SUB MERCK | Beta-amino tetrahydroimidazo (1, 2-a) pyrazines and tetrahydrotrioazolo (4, 3-a) pyrazines as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes |
Jan, 2023
(2 years ago) | |
|
US7326708 (Pediatric) | MSD SUB MERCK | Phosphoric acid salt of a dipeptidyl peptidase-IV inhibitor |
May, 2027
(1 year, 11 months from now) | |
| US8414921 | MSD SUB MERCK | Pharmaceutical compositions of combinations of dipeptidyl peptidase-4 inhibitors with metformin |
Jul, 2028
(3 years from now) | |
|
US8414921 (Pediatric) | MSD SUB MERCK | Pharmaceutical compositions of combinations of dipeptidyl peptidase-4 inhibitors with metformin |
Jan, 2029
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Oct 16, 2011 |
| M(M-244) | Aug 12, 2022 |
| M(M-187) | Dec 04, 2023 |
| Pediatric Exclusivity(PED) | Jun 04, 2024 |
Drugs and Companies using METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE ingredient
NCE-1 date: 05 June, 2023
Market Authorisation Date: 30 March, 2007
Treatment: Method of treating type 2 diabetes mellitus by administering a dipeptidyl peptidase-iv inhibitor; Method of treating type 2 diabetes mellitus by administering a dipeptidyl peptidase-4 inhibitor in com...
Dosage: TABLET
How can I launch a generic of JANUMET before it's drug patent expiration?
More Information on Dosage
JANUMET family patents
15. Januvia patent expiration
JANUVIA's oppositions filed in EPO
JANUVIA IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7326708 | MERCK SHARP DOHME | Phosphoric acid salt of a dipeptidyl peptidase-IV inhibitor |
Nov, 2026
(1 year, 5 months from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6303661 | MERCK SHARP DOHME | Use of dipeptidyl peptidase IV effectors for lowering the blood glucose level in mammals |
Apr, 2017
(8 years ago) | |
| US7078381 | MERCK SHARP DOHME | Method of regulating glucose metabolism, and reagents related thereto |
Feb, 2019
(6 years ago) | |
| US7459428 | MERCK SHARP DOHME | Method of regulating glucose metabolism, and reagents related thereto |
Feb, 2019
(6 years ago) | |
| US6890898 | MERCK SHARP DOHME | Method of regulating glucose metabolism, and reagents related thereto |
Feb, 2019
(6 years ago) | |
| US6699871 | MERCK SHARP DOHME | Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes |
Jul, 2022
(2 years ago) | |
| US7125873 | MERCK SHARP DOHME | Beta-amino tetrahydroimidazo (1, 2-a) pyrazines and tetrahydrotrioazolo (4, 3-a) pyrazines as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes |
Jul, 2022
(2 years ago) | |
|
US6699871 (Pediatric) | MERCK SHARP DOHME | Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes |
Jan, 2023
(2 years ago) | |
|
US7125873 (Pediatric) | MERCK SHARP DOHME | Beta-amino tetrahydroimidazo (1, 2-a) pyrazines and tetrahydrotrioazolo (4, 3-a) pyrazines as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes |
Jan, 2023
(2 years ago) | |
|
US7326708 (Pediatric) | MERCK SHARP DOHME | Phosphoric acid salt of a dipeptidyl peptidase-IV inhibitor |
May, 2027
(1 year, 11 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Oct 16, 2011 |
| M(M-244) | Aug 12, 2022 |
| M(M-187) | Dec 04, 2023 |
| Pediatric Exclusivity(PED) | Jun 04, 2024 |
Drugs and Companies using SITAGLIPTIN PHOSPHATE ingredient
NCE-1 date: 05 June, 2023
Market Authorisation Date: 16 October, 2006
Treatment: Method of treating type 2 diabetes mellitus by administering a dipeptidyl peptidase-iv inhibitor; Method of treating type 2 diabetes mellitus by administering a dipeptidyl peptidase-iv inhibitor in co...
Dosage: TABLET
How can I launch a generic of JANUVIA before it's drug patent expiration?
More Information on Dosage
JANUVIA family patents
16. Kimyrsa patent expiration
KIMYRSA's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9649352 | MELINTA THERAP | High purity oritavancin and method of producing same |
Jul, 2035
(10 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8420592 | MELINTA THERAP | Methods of treatment using single doses of oritavancin |
Aug, 2029
(4 years from now) | |
| US9682061 | MELINTA THERAP | Methods of treating bacterial infections using oritavancin |
Apr, 2030
(4 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Aug 06, 2019 |
| New Product(NP) | Mar 12, 2024 |
| Generating Antibiotic Incentives Now(GAIN) | Aug 06, 2024 |
Drugs and Companies using ORITAVANCIN DIPHOSPHATE ingredient
NCE-1 date: 07 August, 2023
Market Authorisation Date: 12 March, 2021
Treatment: Treatment of acute bacterial skin and skin structure infections with a single dose of 1200mg oritavancin or its single dose equivalent
Dosage: POWDER
More Information on Dosage
KIMYRSA family patents
17. Mayzent patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7939519 | NOVARTIS | Immunosuppresant compounds and compositions |
Aug, 2028
(3 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8492441 | NOVARTIS | Dosage regimen of an S1P receptor agonist |
Nov, 2030
(5 years from now) | |
| US12071402 | NOVARTIS | Immunosuppressant formulations |
Jan, 2032
(6 years from now) | |
| US11944602 | NOVARTIS | Treatment of autoimmune disease in a patient receiving additionally a beta-blocker |
Jul, 2036
(11 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Mar 26, 2024 |
| M(M-274) | Mar 01, 2025 |
Drugs and Companies using SIPONIMOD ingredient
NCE-1 date: 27 March, 2023
Market Authorisation Date: 26 March, 2019
Treatment: A method of treating multiple sclerosis by administering siponimod using a titration scheme to reach a maintenance dose; Treatment of relapsing forms of multiple sclerosis (ms), to include clinically ...
Dosage: TABLET
How can I launch a generic of MAYZENT before it's drug patent expiration?
More Information on Dosage
MAYZENT family patents
18. Multrys patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12150957 | AM REGENT | Trace element compositions, methods of making and use |
Jul, 2041
(16 years from now) | |
| US12150956 | AM REGENT | Trace element compositions, methods of making and use |
Jul, 2041
(16 years from now) | |
| US11786548 | AM REGENT | Trace element compositions, methods of making and use |
Jul, 2041
(16 years from now) | |
| US11998565 | AM REGENT | Trace element compositions, methods of making and use |
Jul, 2041
(16 years from now) | |
| US11975022 | AM REGENT | Trace element compositions, methods of making and use |
Jul, 2041
(16 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Apr 30, 2024 |
Drugs and Companies using CUPRIC SULFATE; MANGANESE SULFATE; SELENIOUS ACID; ZINC SULFATE ingredient
NCE-1 date: 01 May, 2023
Market Authorisation Date: 30 June, 2021
Treatment: Neonatal and pediatric patients weighing less than 10 kg as a source of zinc, copper, manganese, and selenium for parenteral nutrition when oral or enteral nutrition is not possible, insufficient, or ...
Dosage: SOLUTION
More Information on Dosage
MULTRYS family patents
19. Myrbetriq patent expiration
MYRBETRIQ's oppositions filed in EPO
MYRBETRIQ IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6699503 | APGDI | Hydrogel-forming sustained-release preparation |
Sep, 2013
(11 years ago) | |
| US6346532 | APGDI | Amide derivatives or salts thereof |
Oct, 2018
(6 years ago) | |
| US6562375 | APGDI | Stable pharmaceutical composition for oral use |
Aug, 2020
(4 years ago) | |
|
US6346532 (Pediatric) | APGDI | Amide derivatives or salts thereof |
Sep, 2022
(2 years ago) | |
| US7342117 | APGDI | α-form or β-form crystal of acetanilide derivative |
Nov, 2023
(1 year, 6 months ago) | |
| US8835474 | APGDI | Remedy for overactive bladder comprising acetic acid anilide derivative as the active ingredient |
Nov, 2023
(1 year, 6 months ago) | |
| US7982049 | APGDI | α-form or β-form crystal of acetanilide derivative |
Nov, 2023
(1 year, 6 months ago) | |
| USRE44872 | APGDI | Remedy for overactive bladder comprising acetic acid anilide derivative as the active ingredient |
Nov, 2023
(1 year, 6 months ago) | |
| US7750029 | APGDI | Remedy for overactive bladder comprising acetic acid anilide derivative as the active ingredient |
Dec, 2023
(1 year, 5 months ago) | |
|
US7342117 (Pediatric) | APGDI | α-form or β-form crystal of acetanilide derivative |
May, 2024
(1 year, 24 days ago) | |
|
US8835474 (Pediatric) | APGDI | Remedy for overactive bladder comprising acetic acid anilide derivative as the active ingredient |
May, 2024
(1 year, 24 days ago) | |
|
USRE44872 (Pediatric) | APGDI | Remedy for overactive bladder comprising acetic acid anilide derivative as the active ingredient |
May, 2024
(1 year, 24 days ago) | |
|
US7982049 (Pediatric) | APGDI | α-form or β-form crystal of acetanilide derivative |
May, 2024
(1 year, 24 days ago) | |
| US8772315 | APGDI | Pharmaceutical composition for treating overactive bladder |
Oct, 2028
(3 years from now) | |
|
US8772315 (Pediatric) | APGDI | Pharmaceutical composition for treating overactive bladder |
Apr, 2029
(3 years from now) | |
| US12059409 | APGDI | Pharmaceutical composition for modified release |
Sep, 2029
(4 years from now) | |
| US11707451 | APGDI | Pharmaceutical composition for modified release |
Sep, 2029
(4 years from now) | |
| US12097189 | APGDI | Pharmaceutical composition for modified release |
Sep, 2029
(4 years from now) | |
| US10842780 | APGDI | Pharmaceutical composition for modified release |
Sep, 2029
(4 years from now) | |
|
US11707451 (Pediatric) | APGDI | Pharmaceutical composition for modified release |
Mar, 2030
(4 years from now) | |
|
US10842780 (Pediatric) | APGDI | Pharmaceutical composition for modified release |
Mar, 2030
(4 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jun 28, 2017 |
| New Indication(I-777) | Apr 27, 2021 |
| New Indication(I-855) | Mar 25, 2024 |
| Pediatric Exclusivity(PED) | Sep 25, 2024 |
Drugs and Companies using MIRABEGRON ingredient
NCE-1 date: 26 September, 2023
Market Authorisation Date: 28 June, 2012
Treatment: For the treatment of overactive bladder (oab) with symptoms of urge urinary incontinence, urgency, and urinary frequency; Treatment of overactive bladder with symptoms of urge urinary incontinence, ur...
Dosage: TABLET, EXTENDED RELEASE
How can I launch a generic of MYRBETRIQ before it's drug patent expiration?
More Information on Dosage
MYRBETRIQ family patents
20. Nourianz patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7541363 | KYOWA KIRIN | Microcrystal |
Nov, 2024
(6 months ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7727994 | KYOWA KIRIN | Methods of treating patients suffering from movement disorders |
Jan, 2023
(2 years ago) | |
| US8318201 | KYOWA KIRIN | Method of stabilizing diarylvinylene compound |
Sep, 2027
(2 years from now) | |
| US7727993 | KYOWA KIRIN | Administering adenosine A2A receptor antagonist to reduce or suppress side effects of parkinson's disease therapy |
Jan, 2028
(2 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Aug 27, 2024 |
Drugs and Companies using ISTRADEFYLLINE ingredient
NCE-1 date: 28 August, 2023
Market Authorisation Date: 27 August, 2019
Treatment: A method of reducing off time from l-dopa therapy, comprising administering, to a human patient with parkinson's disease, an effective amount of istradefylline, wherein the patient currently receives ...
Dosage: TABLET
More Information on Dosage
NOURIANZ family patents
21. Nubeqa patent expiration
NUBEQA's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US11046713 | BAYER HEALTHCARE | Androgen receptor modulating compounds |
Oct, 2030
(5 years from now) | |
| US10711013 | BAYER HEALTHCARE | Androgen receptor modulating compounds |
Oct, 2030
(5 years from now) | |
| US9657003 | BAYER HEALTHCARE | Androgen receptor modulating compounds |
Oct, 2030
(5 years from now) | |
| US8975254 | BAYER HEALTHCARE | Androgen receptor modulating compounds |
Mar, 2033
(7 years from now) | |
| US10010530 | BAYER HEALTHCARE | Carboxamide derivative and its diastereomers in stable crystalline form |
Jan, 2036
(10 years from now) | |
| US10383853 | BAYER HEALTHCARE | Carboxamide derivative and its diastereomers in stable crystalline form |
Jan, 2036
(10 years from now) | |
| US11168058 | BAYER HEALTHCARE | Manufacture of a crystalline pharmaceutical product |
Feb, 2038
(12 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10835515 | BAYER HEALTHCARE | Carboxamide derivative and its diastereomers in stable crystalline form |
Jan, 2036
(10 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jul 30, 2024 |
| New Indication(I-900) | Aug 05, 2025 |
Drugs and Companies using DAROLUTAMIDE ingredient
NCE-1 date: 31 July, 2023
Market Authorisation Date: 30 July, 2019
Treatment: Treatment of patients with non-metastatic castration resistant prostate cancer
Dosage: TABLET
More Information on Dosage
NUBEQA family patents
22. Orbactiv patent expiration
ORBACTIV's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US5998581 | MELINTA THERAP | Reductive alkylation of glycopeptide antibiotics |
Nov, 2017
(7 years ago) | |
| US5840684 | MELINTA THERAP | Glycopeptide antibiotic derivatives |
Nov, 2020
(4 years ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8420592 | MELINTA THERAP | Methods of treatment using single doses of oritavancin |
Aug, 2029
(4 years from now) | |
| US9682061 | MELINTA THERAP | Methods of treating bacterial infections using oritavancin |
Apr, 2030
(4 years from now) | |
| US9649352 | MELINTA THERAP | High purity oritavancin and method of producing same |
Jul, 2035
(10 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Aug 06, 2019 |
| Generating Antibiotic Incentives Now(GAIN) | Aug 06, 2024 |
Drugs and Companies using ORITAVANCIN DIPHOSPHATE ingredient
NCE-1 date: 07 August, 2023
Market Authorisation Date: 06 August, 2014
Treatment: Treatment of bacterial skin and skin structure infections using a single dose; Treatment of bacterial skin and skin structure infections
Dosage: POWDER
More Information on Dosage
ORBACTIV family patents
23. Oxbryta patent expiration
OXBRYTA's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US10034879 | GLOBAL BLOOD THERAPS | Substituted benzaldehyde compounds and methods for their use in increasing tissue oxygenation |
Dec, 2032
(7 years from now) | |
| US10806733 | GLOBAL BLOOD THERAPS | Substituted benzaldehyde compounds and methods for their use in increasing tissue oxygenation |
Dec, 2032
(7 years from now) | |
| US9018210 | GLOBAL BLOOD THERAPS | Substituted benzaldehyde compounds and methods for their use in increasing tissue oxygenation |
Nov, 2033
(8 years from now) | |
| US9447071 | GLOBAL BLOOD THERAPS | Crystalline polymorphs of the free base of 2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde |
Feb, 2035
(9 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10017491 | GLOBAL BLOOD THERAPS | Compounds and uses thereof for the modulation of hemoglobin |
Dec, 2032
(7 years from now) | |
| US9248199 | GLOBAL BLOOD THERAPS | 1:1 adducts of sickle hemoglobin |
Jan, 2034
(8 years from now) | |
| US11452720 | GLOBAL BLOOD THERAPS | Crystalline polymorphs of the free base of 2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde |
Feb, 2035
(9 years from now) | |
| US10722502 | GLOBAL BLOOD THERAPS | Crystalline polymorphs of the free base of 2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde |
Feb, 2035
(9 years from now) | |
| US11020382 | GLOBAL BLOOD THERAPS | Dosing regimens for 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde |
Dec, 2036
(11 years from now) | |
| US11944612 | GLOBAL BLOOD THERAPS | Dosing regimens for 2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde |
Dec, 2036
(11 years from now) | |
| US10493035 | GLOBAL BLOOD THERAPS | Tablets comprising 2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde |
Oct, 2037
(12 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Nov 25, 2024 |
| Orphan Drug Exclusivity(ODE-281) | Nov 25, 2026 |
| Orphan Drug Exclusivity(ODE-394) | Dec 17, 2028 |
Drugs and Companies using VOXELOTOR ingredient
NCE-1 date: 26 November, 2023
Market Authorisation Date: 14 October, 2022
Treatment: Treatment of sickle cell disease by administering voxelotor, as recited in claim 2; Treating sickle cell disease by administering voxelotor and another active agent; Increasing hemoglobin to treat sic...
Dosage: TABLET
More Information on Dosage
OXBRYTA family patents
24. Piqray patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8476268 | NOVARTIS | Pyrrolidine-1,2-dicarboxamide derivatives |
Sep, 2029
(4 years from now) | |
| US8227462 | NOVARTIS | Pyrrolidine-1,2-dicarboxamide derivatives |
Apr, 2033
(7 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | May 24, 2024 |
| New Indication(I-937) | Jan 18, 2027 |
Drugs and Companies using ALPELISIB ingredient
NCE-1 date: 25 May, 2023
Market Authorisation Date: 24 May, 2019
Treatment: In combination with fulvestrant for treatment of adults with hr-positive, her-2-negative, pik3ca-mutated, advanced or metastatic breast cancer
Dosage: TABLET
More Information on Dosage
PIQRAY family patents
25. Pradaxa patent expiration
PRADAXA's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US6087380 | BOEHRINGER INGELHEIM | Disubstituted bicyclic heterocycles, the preparations and the use thereof as pharmaceutical compositions |
Dec, 2021
(3 years ago) | |
| US7932273 | BOEHRINGER INGELHEIM | 3-[(2-{[4-(hexyloxycarbonylaminoiminomethyl) phenylamino]methyl}-1-methyl-1H-benzimidazol-5-carbonyl)pyridin-2-ylamino]propionic acid ethylester methansulfonate and its use as a medicament |
Sep, 2025
(3 months from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6087380 | BOEHRINGER INGELHEIM | Disubstituted bicyclic heterocycles, the preparations and the use thereof as pharmaceutical compositions |
Feb, 2018
(7 years ago) | |
|
US6087380 (Pediatric) | BOEHRINGER INGELHEIM | Disubstituted bicyclic heterocycles, the preparations and the use thereof as pharmaceutical compositions |
Jun, 2022
(2 years ago) | |
| US9925174 | BOEHRINGER INGELHEIM | Administration form for the oral application of 3-[(2-{[4-(hexyloxycarbonyl-amino-imino-methyl)-phenylamino]-methyl}-1-methyl-1 H-benzimidazol acid ethyl ester and the salts thereof |
Jun, 2023
(1 year, 11 months ago) | |
|
US9925174 (Pediatric) | BOEHRINGER INGELHEIM | Administration form for the oral application of 3-[(2-{[4-(hexyloxycarbonyl-amino-imino-methyl)-phenylamino]-methyl}-1-methyl-1 H-benzimidazol acid ethyl ester and the salts thereof |
Dec, 2023
(1 year, 5 months ago) | |
|
US7932273 (Pediatric) | BOEHRINGER INGELHEIM | 3-[(2-{[4-(hexyloxycarbonylaminoiminomethyl) phenylamino]methyl}-1-methyl-1H-benzimidazol-5-carbonyl)pyridin-2-ylamino]propionic acid ethylester methansulfonate and its use as a medicament |
Mar, 2026
(9 months from now) | |
| US7866474 | BOEHRINGER INGELHEIM | Film container |
Aug, 2027
(2 years from now) | |
|
US7866474 (Pediatric) | BOEHRINGER INGELHEIM | Film container |
Mar, 2028
(2 years from now) | |
| US9034822 | BOEHRINGER INGELHEIM | Methods of using antibodies during anticoagulant therapy of dabigatran and/or related compounds |
Jan, 2031
(5 years from now) | |
|
US9034822 (Pediatric) | BOEHRINGER INGELHEIM | Methods of using antibodies during anticoagulant therapy of dabigatran and/or related compounds |
Jul, 2031
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Oct 19, 2015 |
| New Indication(I-682) | Apr 04, 2017 |
| New Indication(I-683) | Apr 04, 2017 |
| M(M-168) | Nov 20, 2018 |
| New Strength(NS) | Nov 20, 2018 |
| New Indication(I-862) | Jun 21, 2024 |
| New Product(NP) | Jun 21, 2024 |
| Pediatric Exclusivity(PED) | Dec 21, 2024 |
Drugs and Companies using DABIGATRAN ETEXILATE MESYLATE ingredient
NCE-1 date: 22 December, 2023
Market Authorisation Date: 19 October, 2010
Treatment: Inhibition of thrombin; Method of reversing the anticoagulant effect of dabigatran using idarucizumab; Prophylaxis or treatment of venous and arterial thrombotic disease
Dosage: CAPSULE
How can I launch a generic of PRADAXA before it's drug patent expiration?
More Information on Dosage
PRADAXA family patents
26. Rinvoq patent expiration
RINVOQ's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8962629 | ABBVIE | Tricyclic compounds |
Jan, 2031
(5 years from now) | |
| USRE47221 | ABBVIE | Tricyclic compounds |
Aug, 2033
(8 years from now) | |
| US12110298 | ABBVIE | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
Oct, 2036
(11 years from now) | |
| US11661425 | ABBVIE | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
Oct, 2036
(11 years from now) | |
| US11773105 | ABBVIE | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]- pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
Oct, 2036
(11 years from now) | |
| US9951080 | ABBVIE | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-alpha]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
Oct, 2036
(11 years from now) | |
| US11680069 | ABBVIE | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
Oct, 2036
(11 years from now) | |
| US11718627 | ABBVIE | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
Oct, 2036
(11 years from now) | |
| US11186584 | ABBVIE | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
Oct, 2036
(11 years from now) | |
| US10981923 | ABBVIE | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[l,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
Oct, 2036
(11 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9963459 | ABBVIE | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-alpla]pyrrolo[2,3-e]-pyrazin-8-YL)-N-(2,2,2-Trifluoroethyl)pyrrol and solid state forms thereof |
Oct, 2036
(11 years from now) | |
| US12116373 | ABBVIE | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
Oct, 2036
(11 years from now) | |
| US12077545 | ABBVIE | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
Oct, 2036
(11 years from now) | |
| US12134621 | ABBVIE | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
Oct, 2036
(11 years from now) | |
| US10730883 | ABBVIE | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
Oct, 2036
(11 years from now) | |
| US10981924 | ABBVIE | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
Oct, 2036
(11 years from now) | |
| US10202393 | ABBVIE | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-α]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
Oct, 2036
(11 years from now) | |
| US10344036 | ABBVIE | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-#a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-#carboxamide and solid state forms thereof |
Oct, 2036
(11 years from now) | |
| US11198697 | ABBVIE | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
Oct, 2036
(11 years from now) | |
| US12103933 | ABBVIE | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
Oct, 2036
(11 years from now) | |
| US12091415 | ABBVIE | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
Oct, 2036
(11 years from now) | |
| US12110297 | ABBVIE | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
Oct, 2036
(11 years from now) | |
| US11787815 | ABBVIE | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
Oct, 2036
(11 years from now) | |
| US11976077 | ABBVIE | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-α]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms therof |
Oct, 2036
(11 years from now) | |
| US11512092 | ABBVIE | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
Oct, 2036
(11 years from now) | |
| US11795175 | ABBVIE | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
Oct, 2036
(11 years from now) | |
| US11365198 | ABBVIE | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
Oct, 2036
(11 years from now) | |
| US11780848 | ABBVIE | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1- carboxamide and solid state forms thereof |
Oct, 2036
(11 years from now) | |
| US10519164 | ABBVIE | Processes for the preparation of (3S,4R)-3,ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
Oct, 2036
(11 years from now) | |
| US11535624 | ABBVIE | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-α]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
Oct, 2036
(11 years from now) | |
| US11773106 | ABBVIE | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
Oct, 2036
(11 years from now) | |
| US11993605 | ABBVIE | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
Oct, 2036
(11 years from now) | |
| US11993606 | ABBVIE | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
Oct, 2036
(11 years from now) | |
| US10597400 | ABBVIE | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carb oxamide and solid state forms thereof |
Oct, 2036
(11 years from now) | |
| US10995095 | ABBVIE | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carb oxamide and solid state forms thereof |
Oct, 2036
(11 years from now) | |
| US11767326 | ABBVIE | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
Oct, 2036
(11 years from now) | |
| US11535626 | ABBVIE | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1 carboxamide and solid state forms thereof |
Oct, 2036
(11 years from now) | |
| US11535625 | ABBVIE | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
Oct, 2036
(11 years from now) | |
| US11524964 | ABBVIE | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
Oct, 2036
(11 years from now) | |
| US10550126 | ABBVIE | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-A]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
Oct, 2036
(11 years from now) | |
| US11780847 | ABBVIE | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1- carboxamide and solid state forms thereof |
Oct, 2036
(11 years from now) | |
| US11607411 | ABBVIE | Methods of treating Crohn's disease and ulcerative colitis |
Mar, 2038
(12 years from now) | |
| US11564922 | ABBVIE | Methods of treating crohn's disease and ulcerative colitis |
Mar, 2038
(12 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Aug 16, 2024 |
| New Indication(I-880) | Dec 14, 2024 |
| New Indication(I-883) | Jan 14, 2025 |
| New Indication(I-886) | Mar 16, 2025 |
| New Indication(I-888) | Apr 29, 2025 |
| New Indication(I-919) | May 18, 2026 |
| New Indication(I-946) | Apr 26, 2027 |
| New Patient Population(NPP) | Apr 26, 2027 |
| Orphan Drug Exclusivity(ODE-481) | Apr 26, 2031 |
Drugs and Companies using UPADACITINIB ingredient
NCE-1 date: 17 August, 2023
Market Authorisation Date: 16 August, 2019
Treatment: Treatment of adults and pediatric patients 12 years of age and older with refractory, moderate to severe atopic dermatitis whose disease is not adequately controlled with other systemic drug products,...
Dosage: TABLET, EXTENDED RELEASE
More Information on Dosage
RINVOQ family patents
27. Rinvoq Lq patent expiration
RINVOQ LQ's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8962629 | ABBVIE | Tricyclic compounds |
Jan, 2031
(5 years from now) | |
| USRE47221 | ABBVIE | Tricyclic compounds |
Aug, 2033
(8 years from now) | |
| US11718627 | ABBVIE | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
Oct, 2036
(11 years from now) | |
| US11661425 | ABBVIE | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
Oct, 2036
(11 years from now) | |
| US12110298 | ABBVIE | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
Oct, 2036
(11 years from now) | |
| US11680069 | ABBVIE | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
Oct, 2036
(11 years from now) | |
| US10981923 | ABBVIE | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[l,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
Oct, 2036
(11 years from now) | |
| US9951080 | ABBVIE | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-alpha]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
Oct, 2036
(11 years from now) | |
| US11773105 | ABBVIE | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]- pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
Oct, 2036
(11 years from now) | |
| US11186584 | ABBVIE | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
Oct, 2036
(11 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Aug 16, 2024 |
| New Product(NP) | Apr 26, 2027 |
| Orphan Drug Exclusivity(ODE-481) | Apr 26, 2031 |
Drugs and Companies using UPADACITINIB ingredient
NCE-1 date: 17 August, 2023
Market Authorisation Date: 26 April, 2024
Treatment: Treatment of patients 2 years of age and older with active polyarticular juvenile idiopathic arthritis who have had an inadequate response or intolerance to one or more tnf blockers
Dosage: SOLUTION
More Information on Dosage
RINVOQ LQ family patents
28. Rozlytrek patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9029356 | GENENTECH INC | Substituted indazole derivatives active as kinase inhibitors |
Jul, 2028
(3 years from now) | |
| US8299057 | GENENTECH INC | Substituted indazole derivatives active as kinase inhibitors |
Mar, 2029
(3 years from now) | |
| US9085565 | GENENTECH INC | Process for the preparation of N-[5-(3,5-difluoro-benzyl)-1H-indazol-3-yl]-4-(4-methyl-piperazin-1-yl)-2-(tetrahydro-pyran-4-ylamino)-benzamide |
May, 2033
(7 years from now) | |
| US10738037 | GENENTECH INC | Crystalline form of N-[5-(3,5-difluoro-benzyl)-1H-indazol-3-yl]-4-(4-methyl-piperazin-1-yl)-2-(tetrahydro-pyran-4-ylamino)-benzamide |
May, 2037
(11 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9616059 | GENENTECH INC | Substituted indazole derivatives active as kinase inhibitors |
Jul, 2028
(3 years from now) | |
| US9085558 | GENENTECH INC | Substituted indazole derivatives active as kinase inhibitors |
Jul, 2028
(3 years from now) | |
| US9255087 | GENENTECH INC | Substituted indazole derivatives active as kinase inhibitors |
Jul, 2028
(3 years from now) | |
| US8673893 | GENENTECH INC | Substituted indazole derivatives active as kinase inhibitors |
Jul, 2028
(3 years from now) | |
| US9649306 | GENENTECH INC | Treatment of diseases through administration of N-[5-(3,5-difluoro-benzyl)-1H-indazol-3-yl]-4-(4-methyl-piperazin-1-yl)-2-(tetrahydro-pyran-4-ylamino)-benzamide |
May, 2033
(7 years from now) | |
| US10231965 | GENENTECH INC | Molecules for administration to ROS1 mutant cancer cells |
Feb, 2035
(9 years from now) | |
| US10561651 | GENENTECH INC | Methods for treating neuroblastoma |
Feb, 2035
(9 years from now) | |
| US11091469 | GENENTECH INC | Crystalline form of N-[5-(3,5-difluoro-benzyl)-1H-indazol-3-yl]-4-(4-methyl-piperazin-1-yl)-2-(tetrahydro-pyran-4-ylamino)-benzamide |
May, 2037
(11 years from now) | |
| US10398693 | GENENTECH INC | Pharmaceutical compositions and dosage forms |
Jul, 2038
(13 years from now) | |
| US11253515 | GENENTECH INC | Pharmaceutical compositions and dosage forms |
Jul, 2038
(13 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Aug 15, 2024 |
| ODE*(ODE*) | Aug 15, 2026 |
| Orphan Drug Exclusivity(ODE-265) | Aug 15, 2026 |
| Orphan Drug Exclusivity(ODE-313) | Aug 15, 2026 |
| New Product(NP) | Oct 20, 2026 |
| New Patient Population(NPP) | Oct 20, 2026 |
| Orphan Drug Exclusivity(ODE-448) | Oct 20, 2030 |
Drugs and Companies using ENTRECTINIB ingredient
NCE-1 date: 16 August, 2023
Market Authorisation Date: 15 August, 2019
Treatment: Treatment of solid tumors that have a neurotrophic tyrosine receptor kinase (ntrk) gene fusion; Treatment of ros1-positive non-small cell lung cancer; Treatment of neuroblastomas that have a neurotrop...
Dosage: CAPSULE
More Information on Dosage
ROZLYTREK family patents
29. Scenesse patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10076555 | CLIVUNEL INC | Methods of inducing melanogenesis in a subject |
Feb, 2025
(3 months ago) | |
| US8334265 | CLIVUNEL INC | Method of treatment of photodermatoses |
Mar, 2029
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Oct 08, 2024 |
| Orphan Drug Exclusivity(ODE-270) | Oct 08, 2026 |
Drugs and Companies using AFAMELANOTIDE ingredient
NCE-1 date: 09 October, 2023
Market Authorisation Date: 08 October, 2019
Treatment: Increase pain-free light exposure in adult patients with a history of phototoxic reactions from erythropoietic protoporphyria (epp)
Dosage: IMPLANT
More Information on Dosage
SCENESSE family patents
30. Selenious Acid patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12150957 | AM REGENT | Trace element compositions, methods of making and use |
Jul, 2041
(16 years from now) | |
| US11998565 | AM REGENT | Trace element compositions, methods of making and use |
Jul, 2041
(16 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Apr 30, 2024 |
Drugs and Companies using SELENIOUS ACID ingredient
NCE-1 date: 01 May, 2023
Market Authorisation Date: 30 August, 2021
Treatment: Adult and pediatric patients as a source of selenium for parenteral nutrition when oral or enteral nutrition is not possible, insufficient, or contraindicated
Dosage: SOLUTION
More Information on Dosage
SELENIOUS ACID family patents
31. Sivextro patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8420676 | CUBIST PHARMS LLC | Oxazolidinone derivatives |
Feb, 2028
(2 years from now) | |
| US7816379 | CUBIST PHARMS LLC | Oxazolidinone derivatives |
Jun, 2028
(3 years from now) | |
| US9624250 | CUBIST PHARMS LLC | Forms of R)-3-(4-(2-(2-methyltetrazol-5-yl)pyridin-5-yl)-3-fluorophenyl)-5-hydroxymethyl oxazolidin-2-one dihydrogen phosphate |
Feb, 2030
(4 years from now) | |
| US10442829 | CUBIST PHARMS LLC | Forms of R)-3-(4-(2-(2-methyltetrazol-5-yl)pyridin-5-yl)-3-fluorophenyl)-5-hydroxymethyl oxazolidin-2-one dihydrogen phosphate |
Feb, 2030
(4 years from now) | |
| US8426389 | CUBIST PHARMS LLC | Crystalline form of R)-3-(4-(2-(2-methyltetrazol-5-yl)pyridin-5-yl)-3-fluorophenyl)-5-hydroxymethyl oxazolidin-2-one dihydrogen phosphate |
Dec, 2030
(5 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9988406 | CUBIST PHARMS LLC | Forms of R)-3-(4-(2-(2-methyltetrazol-5-yl)pyridin-5-yl)-3-fluorophenyl)-5-hydroxymethyl oxazolidin-2-one dihydrogen phosphate |
Feb, 2030
(4 years from now) | |
| US10065947 | CUBIST PHARMS LLC | Forms of R)-3-(4-(2-(2-methyltetrazol-5-yl)pyridin-5-yl)-3-fluorophenyl)-5-hydroxymethyl oxazolidin-2-one dihydrogen phosphate |
Feb, 2030
(4 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jun 20, 2019 |
| Generating Antibiotic Incentives Now(GAIN) | Jun 20, 2024 |
| New Patient Population(NPP) | Apr 04, 2028 |
Drugs and Companies using TEDIZOLID PHOSPHATE ingredient
NCE-1 date: 21 June, 2023
Market Authorisation Date: 20 June, 2014
Treatment: Method of treating bacterial infections; Method of treating acute bacterial skin and skin structure infections (absssi) caused by designated susceptible bacteria
Dosage: TABLET; POWDER
More Information on Dosage
SIVEXTRO family patents
32. Sovaldi patent expiration
SOVALDI's oppositions filed in EPO
SOVALDI IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9085573 | GILEAD SCIENCES INC | NA |
Mar, 2028
(2 years from now) | |
| US8334270 | GILEAD SCIENCES INC | NA |
Mar, 2028
(2 years from now) | |
| US8580765 | GILEAD SCIENCES INC | NA |
Mar, 2028
(2 years from now) | |
| US7964580 | GILEAD SCIENCES INC | NA |
Mar, 2029
(3 years from now) | |
| US8633309 | GILEAD SCIENCES INC | Nucleoside phosphoramidates |
Mar, 2029
(3 years from now) | |
| US9284342 | GILEAD SCIENCES INC | Nucleoside phosphoramidates |
Sep, 2030
(5 years from now) | |
| US8618076 | GILEAD SCIENCES INC | Nucleoside phosphoramidates |
Dec, 2030
(5 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US8334270 (Pediatric) | GILEAD SCIENCES INC | NA |
Sep, 2028
(3 years from now) | |
|
US8580765 (Pediatric) | GILEAD SCIENCES INC | NA |
Sep, 2028
(3 years from now) | |
|
US9085573 (Pediatric) | GILEAD SCIENCES INC | NA |
Sep, 2028
(3 years from now) | |
| US8889159 | GILEAD SCIENCES INC | Compositions and methods for treating hepatitis C virus |
Mar, 2029
(3 years from now) | |
| US9549941 | GILEAD SCIENCES INC | Compositions and methods for treating hepatitis C virus |
Mar, 2029
(3 years from now) | |
|
US8633309 (Pediatric) | GILEAD SCIENCES INC | Nucleoside phosphoramidates |
Sep, 2029
(4 years from now) | |
|
US7964580 (Pediatric) | GILEAD SCIENCES INC | NA |
Sep, 2029
(4 years from now) | |
|
US8889159 (Pediatric) | GILEAD SCIENCES INC | Compositions and methods for treating hepatitis C virus |
Sep, 2029
(4 years from now) | |
|
US9549941 (Pediatric) | GILEAD SCIENCES INC | Compositions and methods for treating hepatitis C virus |
Sep, 2029
(4 years from now) | |
|
US9284342 (Pediatric) | GILEAD SCIENCES INC | Nucleoside phosphoramidates |
Mar, 2031
(5 years from now) | |
|
US8618076 (Pediatric) | GILEAD SCIENCES INC | Nucleoside phosphoramidates |
Jun, 2031
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Dec 06, 2018 |
| New Patient Population(NPP) | Apr 07, 2020 |
| Orphan Drug Exclusivity(ODE) | Apr 07, 2024 |
| ODE*(ODE*) | Aug 28, 2026 |
| Orphan Drug Exclusivity(ODE-135) | Apr 07, 2024 |
| Pediatric Exclusivity(PED) | Oct 07, 2024 |
| Orphan Drug Exclusivity(ODE-258) | Aug 28, 2026 |
Drugs and Companies using SOFOSBUVIR ingredient
NCE-1 date: 08 October, 2023
Market Authorisation Date: 28 August, 2019
Treatment: For the treatment of hepatitis c; For the treatment of genotype 1, 2, 3 or 4 chronic hepatitis c virus (hcv) infection as a component of a combination antiviral treatment regimen with ribavirin
Dosage: TABLET
How can I launch a generic of SOVALDI before it's drug patent expiration?
More Information on Dosage
SOVALDI family patents
33. Sunosi patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9604917 | AXSOME MALTA | Treatment of sleep-wake disorders |
Jun, 2026
(1 year, 9 days from now) | |
| US11753368 | AXSOME MALTA | Treatment of sleep-wake disorders |
Jun, 2026
(1 year, 9 days from now) | |
| US8877806 | AXSOME MALTA | Treatment of sleep-wake disorders |
Jun, 2026
(1 year, 9 days from now) | |
| US12209059 | AXSOME MALTA | Treatment of sleep-wake disorders |
Jun, 2026
(1 year, 9 days from now) | |
| US10351517 | AXSOME MALTA | Treatment of sleep-wake disorders |
Jun, 2026
(1 year, 9 days from now) | |
| US8440715 | AXSOME MALTA | Treatment of sleep-wake disorders |
Jun, 2031
(6 years from now) | |
| US10512609 | AXSOME MALTA | Formulations of (R)-2-amino-3-phenylpropyl carbamate |
Sep, 2037
(12 years from now) | |
| US11998639 | AXSOME MALTA | Formulations of (R)-2-amino-3-phenylpropyl carbamate |
Sep, 2037
(12 years from now) | |
| US11439597 | AXSOME MALTA | Formulations of (R)-2-amino-3-phenylpropyl carbamate |
Sep, 2037
(12 years from now) | |
| US10195151 | AXSOME MALTA | Formulations of (R)-2-amino-3-phenylpropyl carbamate |
Sep, 2037
(12 years from now) | |
| US11648232 | AXSOME MALTA | Methods and compositions for treating excessive sleepiness |
Jun, 2038
(13 years from now) | |
| US10912754 | AXSOME MALTA | Methods and compositions for treating excessive sleepiness |
Jun, 2038
(13 years from now) | |
| US11865098 | AXSOME MALTA | Methods and compositions for treating excessive sleepiness |
Jun, 2038
(13 years from now) | |
| US10959976 | AXSOME MALTA | Methods and compositions for treating excessive sleepiness |
Jun, 2038
(13 years from now) | |
| US11560354 | AXSOME MALTA | Compositions comprising (R)-2-amino-3-phenylpropyl carbamate and uses thereof |
Mar, 2039
(13 years from now) | |
| US11986455 | AXSOME MALTA | Methods of providing solriamfetol therapy to subjects with impaired renal function |
Mar, 2040
(14 years from now) | |
| US11857528 | AXSOME MALTA | Methods of providing solriamfetol therapy to subjects with impaired renal function |
Mar, 2040
(14 years from now) | |
| US11850228 | AXSOME MALTA | Methods of providing solriamfetol therapy to subjects with impaired renal function |
Mar, 2040
(14 years from now) | |
| US12194016 | AXSOME MALTA | Methods of providing solriamfetol therapy to subjects with impaired renal function |
Mar, 2040
(14 years from now) | |
| US11986454 | AXSOME MALTA | Methods of providing solriamfetol therapy to subjects with impaired renal function |
Mar, 2040
(14 years from now) | |
| US11850226 | AXSOME MALTA | Methods of providing solriamfetol therapy to subjects with impaired renal function |
Mar, 2040
(14 years from now) | |
| US11839599 | AXSOME MALTA | Methods of providing solriamfetol therapy to subjects with impaired renal function |
Mar, 2040
(14 years from now) | |
| US11969404 | AXSOME MALTA | Methods of providing solriamfetol therapy to subjects with impaired renal function |
Mar, 2040
(14 years from now) | |
| US10940133 | AXSOME MALTA | Methods of providing solriamfetol therapy to subjects with impaired renal function |
Mar, 2040
(14 years from now) | |
| US11839598 | AXSOME MALTA | Methods of providing solriamfetol therapy to subjects with impaired renal function |
Mar, 2040
(14 years from now) | |
| US11850227 | AXSOME MALTA | Methods of providing solriamfetol therapy to subjects with impaired renal function |
Mar, 2040
(14 years from now) | |
| US11160779 | AXSOME MALTA | Methods of providing solriamfetol therapy to subjects with impaired renal function |
Mar, 2040
(14 years from now) | |
| US12005036 | AXSOME MALTA | Methods of administering solriamfetol to lactating women |
Dec, 2042
(17 years from now) | |
| US12036194 | AXSOME MALTA | Methods of administering solriamfetol to lactating women |
Dec, 2042
(17 years from now) | |
| US11779554 | AXSOME MALTA | Methods of administering solriamfetol to lactating women |
Dec, 2042
(17 years from now) | |
| US11872203 | AXSOME MALTA | Methods of administering solriamfetol to lactating women |
Dec, 2042
(17 years from now) | |
| US11872204 | AXSOME MALTA | Methods of administering solriamfetol to lactating women |
Dec, 2042
(17 years from now) | |
| US11793776 | AXSOME MALTA | Methods of administering solriamfetol to lactating women |
Dec, 2042
(17 years from now) | |
| US11771666 | AXSOME MALTA | Methods of administering solriamfetol to lactating women |
Dec, 2042
(17 years from now) | |
| US12090126 | AXSOME MALTA | Methods of administering solriamfetol to lactating women |
Dec, 2042
(17 years from now) | |
| US11771667 | AXSOME MALTA | Methods of administering solriamfetol to lactating women |
Dec, 2042
(17 years from now) | |
| US12102609 | AXSOME MALTA | Methods of administering solriamfetol to lactating women |
Dec, 2042
(17 years from now) | |
| US12064411 | AXSOME MALTA | Methods of administering solriamfetol to lactating women |
Dec, 2042
(17 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jun 17, 2024 |
| Orphan Drug Exclusivity(ODE-254) | Jun 17, 2026 |
Drugs and Companies using SOLRIAMFETOL HYDROCHLORIDE ingredient
NCE-1 date: 18 June, 2023
Market Authorisation Date: 17 June, 2019
Treatment: To improve wakefulness in adult patients with excessive daytime sleepiness associated with narcolepsy or obstructive sleep apnea (osa); Treatment of excessive daytime sleepiness with a dosing regimen ...
Dosage: TABLET
How can I launch a generic of SUNOSI before it's drug patent expiration?
More Information on Dosage
SUNOSI family patents
34. Toviaz patent expiration
TOVIAZ IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7985772 | PFIZER | Derivatives of 3,3-diphenylpropylamines |
May, 2019
(6 years ago) | |
| US7855230 | PFIZER | Derivatives of 3,3-diphenylpropylamines |
May, 2019
(6 years ago) | |
| US8338478 | PFIZER | Derivatives of 3,3-diphenylpropylamines |
May, 2019
(6 years ago) | |
| US7384980 | PFIZER | Derivatives of 3,3-diphenylpropylamines |
May, 2019
(6 years ago) | |
| US6858650 | PFIZER | Stable salts of novel derivatives of 3,3-diphenylpropylamines |
Jul, 2022
(2 years ago) | |
|
US6858650 (Pediatric) | PFIZER | Stable salts of novel derivatives of 3,3-diphenylpropylamines |
Jan, 2023
(2 years ago) | |
| US8088398 | PFIZER | Pharmaceutical compositions comprising fesoterodine |
Jun, 2027
(2 years from now) | |
| US8501723 | PFIZER | Pharmaceutical compositions comprising fesoterodine |
Jun, 2027
(2 years from now) | |
| US7807715 | PFIZER | Pharmaceutical compositions comprising fesoterodine |
Jun, 2027
(2 years from now) | |
|
US8088398 (Pediatric) | PFIZER | Pharmaceutical compositions comprising fesoterodine |
Dec, 2027
(2 years from now) | |
|
US8501723 (Pediatric) | PFIZER | Pharmaceutical compositions comprising fesoterodine |
Dec, 2027
(2 years from now) | |
|
US7807715 (Pediatric) | PFIZER | Pharmaceutical compositions comprising fesoterodine |
Dec, 2027
(2 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Oct 31, 2013 |
| New Indication(I-861) | Jun 17, 2024 |
| Pediatric Exclusivity(PED) | Dec 17, 2024 |
Drugs and Companies using FESOTERODINE FUMARATE ingredient
NCE-1 date: 18 December, 2023
Market Authorisation Date: 31 October, 2008
Treatment: Treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and frequency
Dosage: TABLET, EXTENDED RELEASE
How can I launch a generic of TOVIAZ before it's drug patent expiration?
More Information on Dosage
TOVIAZ family patents
35. Tralement patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12150957 | AM REGENT | Trace element compositions, methods of making and use |
Jul, 2041
(16 years from now) | |
| US12150956 | AM REGENT | Trace element compositions, methods of making and use |
Jul, 2041
(16 years from now) | |
| US11786548 | AM REGENT | Trace element compositions, methods of making and use |
Jul, 2041
(16 years from now) | |
| US11998565 | AM REGENT | Trace element compositions, methods of making and use |
Jul, 2041
(16 years from now) | |
| US11975022 | AM REGENT | Trace element compositions, methods of making and use |
Jul, 2041
(16 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Apr 30, 2024 |
Drugs and Companies using CUPRIC SULFATE; MANGANESE SULFATE; SELENIOUS ACID; ZINC SULFATE ingredient
NCE-1 date: 01 May, 2023
Market Authorisation Date: 30 June, 2021
Treatment: Adult and pediatric patients weighing at least 10 kg as a source of zinc, copper, manganese, and selenium for parenteral nutrition when oral or enteral nutrition is not possible, insufficient, or cont...
Dosage: SOLUTION
More Information on Dosage
TRALEMENT family patents
36. Trikafta (copackaged) patent expiration
TRIKAFTA (COPACKAGED)'s oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8754224 | VERTEX PHARMS INC | Solid forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide |
Dec, 2026
(1 year, 6 months from now) | |
| US11639347 | VERTEX PHARMS INC | Modulators of ATP-binding cassette transporters |
Apr, 2027
(1 year, 10 months from now) | |
| US10239867 | VERTEX PHARMS INC | Modulators of ATP-binding cassette transporters |
Apr, 2027
(1 year, 10 months from now) | |
| US8623905 | VERTEX PHARMS INC | Modulators of ATP-binding cassette transporters |
May, 2027
(1 year, 11 months from now) | |
| US7645789 | VERTEX PHARMS INC | Indole derivatives as CFTR modulators |
May, 2027
(1 year, 11 months from now) | |
| US7495103 | VERTEX PHARMS INC | Modulators of ATP-binding cassette transporters |
May, 2027
(1 year, 11 months from now) | |
| US7776905 | VERTEX PHARMS INC | Modulators of ATP-binding cassette transporters |
Jun, 2027
(2 years from now) | |
| US11426407 | VERTEX PHARMS INC | Modulators of cystic fibrosis transmembrane conductance regulator |
Oct, 2035
(10 years from now) | |
| US10758534 | VERTEX PHARMS INC | NA |
Oct, 2035
(10 years from now) | |
| US11453655 | VERTEX PHARMS INC | Modulator of the cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator |
Dec, 2037
(12 years from now) | |
| US10793547 | VERTEX PHARMS INC | Modulator of the cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator |
Dec, 2037
(12 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8629162 | VERTEX PHARMS INC | Modulators of ATP-binding cassette transporters |
Jun, 2025
(26 days from now) | |
| US8354427 | VERTEX PHARMS INC | Modulators of ATP-binding cassette transporters |
Jul, 2026
(1 year, 1 month from now) | |
| US8410274 | VERTEX PHARMS INC | Solid forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide |
Dec, 2026
(1 year, 6 months from now) | |
| US9670163 | VERTEX PHARMS INC | Solid forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide |
Dec, 2026
(1 year, 6 months from now) | |
| US9931334 | VERTEX PHARMS INC | Solid forms of N[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide |
Dec, 2026
(1 year, 6 months from now) | |
| US9974781 | VERTEX PHARMS INC | Modulators of ATP-binding cassette transporters |
Apr, 2027
(1 year, 10 months from now) | |
| US10022352 | VERTEX PHARMS INC | Modulators of ATP-binding cassette transporters |
Apr, 2027
(1 year, 10 months from now) | |
| US8598181 | VERTEX PHARMS INC | Modulators of ATP-binding cassette transporters |
May, 2027
(1 year, 11 months from now) | |
| US8324242 | VERTEX PHARMS INC | Modulators of ATP-binding cassette transporters |
Aug, 2027
(2 years from now) | |
| US8415387 | VERTEX PHARMS INC | Modulators of ATP-binding cassette transporters |
Nov, 2027
(2 years from now) | |
| US11564916 | VERTEX PHARMS INC | Pharmaceutical composition and administrations thereof |
Aug, 2029
(4 years from now) | |
| US10646481 | VERTEX PHARMS INC | Pharmaceutical composition and administrations thereof |
Aug, 2029
(4 years from now) | |
| US11578062 | VERTEX PHARMS INC | Solid forms of (R)-1(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide |
Mar, 2031
(5 years from now) | |
| US10081621 | VERTEX PHARMS INC | Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide |
Mar, 2031
(5 years from now) | |
| US8883206 | VERTEX PHARMS INC | Pharmaceutical composition and administrations thereof |
Feb, 2033
(7 years from now) | |
| US11752106 | VERTEX PHARMS INC | Pharmaceutical composition and administrations thereof |
Feb, 2033
(7 years from now) | |
| US12214083 | VERTEX PHARMS INC | Pharmaceutical composition and administrations thereof |
Feb, 2033
(7 years from now) | |
| US11147770 | VERTEX PHARMS INC | Pharmaceutical composition and administrations thereof |
Feb, 2033
(7 years from now) | |
| US10272046 | VERTEX PHARMS INC | Pharmaceutical composition and administrations thereof |
Feb, 2033
(7 years from now) | |
| US9012496 | VERTEX PHARMS INC | Pharmaceutical compositions of (R)-1-(2,2-difluorobenzo[D][1,3]dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide and administration thereof |
Jul, 2033
(8 years from now) | |
| US11517564 | VERTEX PHARMS INC | Methods of treatment for cystic fibrosis |
Dec, 2037
(12 years from now) | |
| US11179367 | VERTEX PHARMS INC | Pharmaceutical compositions for treating cystic fibrosis |
Dec, 2037
(12 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Patient Population(NPP) | Jun 08, 2024 |
| New Chemical Entity Exclusivity(NCE) | Oct 21, 2024 |
| New Product(NP) | Apr 26, 2026 |
| Orphan Drug Exclusivity(ODE-275) | Oct 21, 2026 |
| M(M-313) | Dec 20, 2027 |
| ODE*(ODE*) | Dec 21, 2027 |
| Orphan Drug Exclusivity(ODE-323) | Dec 21, 2027 |
| Orphan Drug Exclusivity(ODE-357) | Jun 08, 2028 |
| Orphan Drug Exclusivity(ODE-433) | Apr 26, 2030 |
| Orphan Drug Exclusivity(ODE-512) | Dec 20, 2031 |
Drugs and Companies using ELEXACAFTOR, IVACAFTOR, TEZACAFTOR; IVACAFTOR ingredient
NCE-1 date: 22 October, 2023
Market Authorisation Date: 26 April, 2023
Treatment: Treatment of a moderate to mild clinical phenotype of cf in patients aged 6 years and older who have at least one f508del mutation in the cftr gene or a mutation in the cftr gene that is responsive ba...
Dosage: GRANULES; TABLET
More Information on Dosage
TRIKAFTA (COPACKAGED) family patents
37. Turalio patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8404700 | DAIICHI SANKYO INC | Compounds modulating c-fms and/or c-kit activity and uses therefor |
Nov, 2027
(2 years from now) | |
| US8722702 | DAIICHI SANKYO INC | Compounds modulating c-fms and/or c-kit activity and uses therefor |
Nov, 2027
(2 years from now) | |
| US9169250 | DAIICHI SANKYO INC | Compounds modulating c-fms and/or c-kit activity and uses therefor |
Nov, 2027
(2 years from now) | |
| US7893075 | DAIICHI SANKYO INC | Compounds modulating c-fms and/or c-kit activity and uses therefor |
May, 2033
(7 years from now) | |
| US10730876 | DAIICHI SANKYO INC | Synthesis of a compound that modulates kinases |
May, 2036
(10 years from now) | |
| US9802932 | DAIICHI SANKYO INC | Solid forms of a compound modulating kinases |
May, 2036
(10 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8461169 | DAIICHI SANKYO INC | Compounds modulating c-fms and/or c-kit activity |
Apr, 2028
(2 years from now) | |
| US9358235 | DAIICHI SANKYO INC | Kinase modulation, and indications therefor |
Jun, 2033
(8 years from now) | |
| US10189833 | DAIICHI SANKYO INC | Solid forms of a compound modulating kinases |
May, 2036
(10 years from now) | |
| US10941142 | DAIICHI SANKYO INC | Formulations of a compound modulating kinases |
Jul, 2038
(13 years from now) | |
| US10435404 | DAIICHI SANKYO INC | Formulations of a compound modulating kinases |
Jul, 2038
(13 years from now) | |
| US10961240 | DAIICHI SANKYO INC | Formulations of a compound modulating kinases |
Jul, 2038
(13 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Aug 02, 2024 |
| ODE*(ODE*) | Aug 02, 2026 |
| Orphan Drug Exclusivity(ODE-250) | Aug 02, 2026 |
Drugs and Companies using PEXIDARTINIB HYDROCHLORIDE ingredient
NCE-1 date: 03 August, 2023
Market Authorisation Date: 14 October, 2022
Treatment: Treatment of adult patients with symptomatic tenosynovial giant cell tumor (tgct) associated with severe morbidity or functional limitations and not amenable to improvement with surgery
Dosage: CAPSULE
More Information on Dosage
TURALIO family patents
38. Ubrelvy patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9499545 | ABBVIE | Piperidinone carboxamide azaindane CGRP receptor antagonists |
Nov, 2031
(6 years from now) | |
| US8754096 | ABBVIE | Piperidinone carboxamide azaindane CGRP receptor antagonists |
Jul, 2032
(7 years from now) | |
| US8912210 | ABBVIE | Piperidinone carboxamide azaindane CGRP receptor antagonists |
Dec, 2033
(8 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9833448 | ABBVIE | Piperidinone carboxamide azaindane CGRP receptor antagonists |
Nov, 2031
(6 years from now) | |
| US12168004 | ABBVIE | Treatment of migraine |
Jan, 2035
(9 years from now) | |
| US11925709 | ABBVIE | Tablet formulation for CGRP active compounds |
Jan, 2035
(9 years from now) | |
| US10117836 | ABBVIE | Tablet formulation for CGRP active compounds |
Jan, 2035
(9 years from now) | |
| US11857542 | ABBVIE | Treatment of migraine |
Dec, 2041
(16 years from now) | |
| US12194030 | ABBVIE | Treatment of migraine |
Dec, 2041
(16 years from now) | |
| US12070450 | ABBVIE | Treatment of migraine |
Dec, 2041
(16 years from now) | |
| US11717515 | ABBVIE | Treatment of migraine |
Dec, 2041
(16 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Dec 23, 2024 |
Drugs and Companies using UBROGEPANT ingredient
NCE-1 date: 24 December, 2023
Market Authorisation Date: 23 December, 2019
Treatment: Acute treatment of migraine with or without aura in adults; Acute treatment of migraine with or without aura in a patient with severe renal impairment; Acute treatment of migraine with or without aura...
Dosage: TABLET
More Information on Dosage
UBRELVY family patents
39. Vijoice patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8476268 | NOVARTIS | Pyrrolidine-1,2-dicarboxamide derivatives |
Sep, 2029
(4 years from now) | |
| US8227462 | NOVARTIS | Pyrrolidine-1,2-dicarboxamide derivatives |
Apr, 2033
(7 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | May 24, 2024 |
| Orphan Drug Exclusivity(ODE-396) | Apr 05, 2029 |
Drugs and Companies using ALPELISIB ingredient
NCE-1 date: 25 May, 2023
Market Authorisation Date: 05 April, 2022
Treatment: NA
Dosage: TABLET
More Information on Dosage
VIJOICE family patents
40. Vyleesi (autoinjector) patent expiration
VYLEESI (AUTOINJECTOR)'s oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US6579968 | COSETTE | Compositions and methods for treatment of sexual dysfunction |
Jun, 2021
(3 years ago) | |
| US6794489 | COSETTE | Compositions and methods for treatment of sexual dysfunction |
Jun, 2025
(30 days from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10286034 | COSETTE | Uses of bremelanotide in therapy for female sexual dysfunction |
Nov, 2033
(8 years from now) | |
| US9352013 | COSETTE | Uses of bremelanotide in therapy for female sexual dysfunction |
Nov, 2033
(8 years from now) | |
| US9700592 | COSETTE | Uses of bremelanotide in therapy for female sexual dysfunction |
Nov, 2033
(8 years from now) | |
| US11590209 | COSETTE | Use of bremelanotide in patients with controlled hypertension |
Apr, 2041
(15 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jun 21, 2024 |
Drugs and Companies using BREMELANOTIDE ACETATE ingredient
NCE-1 date: 22 June, 2023
Market Authorisation Date: 21 June, 2019
Treatment: Treatment of hypoactive sexual desire disorder (hsdd); Treating acquired, generalized hypoactive sexual desire disorder (hsdd) in a premenopausal female patient with controlled hypertension by injecti...
Dosage: SOLUTION
More Information on Dosage
VYLEESI (AUTOINJECTOR) family patents
41. Vyndamax patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7214695 | FOLDRX PHARMS | Compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding |
Dec, 2025
(6 months from now) | |
| US9770441 | FOLDRX PHARMS | Crystalline solid forms of 6-carboxy-2-(3,5-dichlorophenyl)-benzoxazole |
Aug, 2035
(10 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7214696 | FOLDRX PHARMS | Compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding |
Dec, 2025
(6 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | May 03, 2024 |
| Orphan Drug Exclusivity(ODE-237) | May 03, 2026 |
Drugs and Companies using TAFAMIDIS ingredient
NCE-1 date: 04 May, 2023
Market Authorisation Date: 03 May, 2019
Treatment: Treatment of the cardiomyopathy of wild type or hereditary transthyretin-mediated amyloidosis (attr-cm)
Dosage: CAPSULE
How can I launch a generic of VYNDAMAX before it's drug patent expiration?
More Information on Dosage
VYNDAMAX family patents
42. Vyndaqel patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8168663 | FOLDRX PHARMS | Pharmaceutically acceptable salt of 6-carboxy-2-(3,5 dichlorophenyl)-benzoxazole, and a pharmaceutical composition comprising the salt thereof |
Dec, 2023
(1 year, 5 months ago) | |
| US7214695 | FOLDRX PHARMS | Compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding |
Dec, 2025
(6 months from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8653119 | FOLDRX PHARMS | Methods for treating transthyretin amyloid diseases |
Dec, 2023
(1 year, 5 months ago) | |
| US7214696 | FOLDRX PHARMS | Compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding |
Dec, 2025
(6 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | May 03, 2024 |
| Orphan Drug Exclusivity(ODE-237) | May 03, 2026 |
Drugs and Companies using TAFAMIDIS MEGLUMINE ingredient
NCE-1 date: 04 May, 2023
Market Authorisation Date: 03 May, 2019
Treatment: Treatment of the cardiomyopathy of wild type or hereditary transthyretin-mediated amyloidosis (attr-cm)
Dosage: CAPSULE
More Information on Dosage
VYNDAQEL family patents
43. Vyondys 53 patent expiration
VYONDYS 53's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9416361 | SAREPTA THERAPS INC | Splice-region antisense composition and method |
May, 2021
(4 years ago) | |
| US9024007 | SAREPTA THERAPS INC | Antisense oligonucleotides for inducing exon skipping and methods of use thereof |
Jun, 2025
(30 days from now) | |
| US10968450 | SAREPTA THERAPS INC | Antisense oligonucleotides for inducing exon skipping and methods of use thereof |
Jun, 2025
(30 days from now) | |
| US10421966 | SAREPTA THERAPS INC | Antisense oligonucleotides for inducing exon skipping and methods of use thereof |
Jun, 2025
(30 days from now) | |
| US10227590 | SAREPTA THERAPS INC | Antisense oligonucleotides for inducing exon skipping and methods of use thereof |
Jun, 2025
(30 days from now) | |
| US9994851 | SAREPTA THERAPS INC | Antisense oligonucleotides for inducing exon skipping and methods of use thereof |
Jun, 2025
(30 days from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10533174 | SAREPTA THERAPS INC | Splice-region antisense composition and method |
May, 2021
(4 years ago) | |
| US10995337 | SAREPTA THERAPS INC | Antisense oligonucleotides for inducing exon skipping and methods of use thereof |
Jun, 2025
(30 days from now) | |
| US10266827 | SAREPTA THERAPS INC | Antisense oligonucleotides for inducing exon skipping and methods of use thereof |
Jun, 2025
(30 days from now) | |
| USRE47691 | SAREPTA THERAPS INC | Antisense oligonucleotides for inducing exon skipping and methods of use thereof |
Jun, 2028
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Dec 12, 2024 |
| Orphan Drug Exclusivity(ODE-280) | Dec 12, 2026 |
Drugs and Companies using GOLODIRSEN ingredient
NCE-1 date: 13 December, 2023
Market Authorisation Date: 12 December, 2019
Treatment: Treatment of duchenne muscular dystrophy (dmd) in patients having a confirmed mutation of the dmd gene that is amenable to exon 53 skipping
Dosage: SOLUTION
More Information on Dosage
VYONDYS 53 family patents
44. Wakix patent expiration
WAKIX's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7169928 | HARMONY | Non-imidazole alkylamines as histamine H3-receptor ligands and their therapeutic applications |
Feb, 2020
(5 years ago) | |
| US8207197 | HARMONY | Monohydrochloride salt of 1-[3-[3-(4-chlorophenyl) propoxy] propyl] -piperidine |
Mar, 2030
(4 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7910605 | HARMONY | Non-imidazole alkylamines as histamine H3- receptor ligands and their therapeutic applications |
Sep, 2022
(2 years ago) | |
| US8354430 | HARMONY | Monohydrochloride salt of 1-[3-[3-(4-chlorophenyl) propoxy]propyl]-piperidine |
Feb, 2026
(8 months from now) | |
| US8486947 | HARMONY | Treatment of Parkinson's disease, obstructive sleep apnea, dementia with Lewy bodies, vascular dementia with non-imidazole alkylamines histamine H3-receptor ligands |
Sep, 2029
(4 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-846) | Oct 13, 2023 |
| New Chemical Entity Exclusivity(NCE) | Aug 14, 2024 |
| Orphan Drug Exclusivity(ODE-255) | Aug 14, 2026 |
| New Patient Population(NPP) | Jun 21, 2027 |
| Orphan Drug Exclusivity(ODE-331) | Oct 13, 2027 |
| Orphan Drug Exclusivity(ODE-489) | Jun 21, 2031 |
Drugs and Companies using PITOLISANT HYDROCHLORIDE ingredient
NCE-1 date: 15 August, 2023
Market Authorisation Date: 14 August, 2019
Treatment: Method of treating cataplexy in patients with narcolepsy
Dosage: TABLET
More Information on Dosage
WAKIX family patents
45. Xphozah patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8969377 | ARDELYX INC | Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders |
Dec, 2029
(4 years from now) | |
| US12016856 | ARDELYX INC | Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders |
Dec, 2029
(4 years from now) | |
| US8541448 | ARDELYX INC | Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders |
Aug, 2033
(8 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10272079 | ARDELYX INC | NHE3-binding compounds and methods for inhibiting phosphate transport |
Apr, 2034
(8 years from now) | |
| US10940146 | ARDELYX INC | NHE3-binding compounds and methods for inhibiting phosphate transport |
Apr, 2034
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Sep 12, 2024 |
| New Product(NP) | Oct 17, 2026 |
Drugs and Companies using TENAPANOR HYDROCHLORIDE ingredient
NCE-1 date: 13 September, 2023
Market Authorisation Date: 17 October, 2023
Treatment: Treatment of hyperphosphatemia; Reduction of serum phosphorus in adults
Dosage: TABLET
More Information on Dosage
XPHOZAH family patents
46. Xpovio patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9714226 | KARYOPHARM THERAPS | Hydrazide containing nuclear transport modulators and uses thereof |
Jul, 2032
(7 years from now) | |
| US8999996 | KARYOPHARM THERAPS | Hydrazide containing nuclear transport modulators and uses thereof |
Jul, 2033
(8 years from now) | |
| US11807629 | KARYOPHARM THERAPS | Polymorphs of Selinexor |
Aug, 2035
(10 years from now) | |
| US10519139 | KARYOPHARM THERAPS | Polymorphs of Selinexor |
Aug, 2035
(10 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9079865 | KARYOPHARM THERAPS | Hydrazide containing nuclear transport modulators and uses thereof |
Jul, 2032
(7 years from now) | |
| US10544108 | KARYOPHARM THERAPS | Hydrazide containing nuclear transport modulators and uses thereof |
Jul, 2032
(7 years from now) | |
| US11787771 | KARYOPHARM THERAPS | Hydrazide containing nuclear transport modulators and uses thereof |
Jul, 2032
(7 years from now) | |
| US11034660 | KARYOPHARM THERAPS | Hydrazide containing nuclear transport modulators and uses thereof |
Jul, 2032
(7 years from now) | |
| US11746102 | KARYOPHARM THERAPS | Polymorphs of selinexor |
Aug, 2035
(10 years from now) | |
| US11753401 | KARYOPHARM THERAPS | Polymorphs of Selinexor |
Aug, 2035
(10 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-837) | Jun 22, 2023 |
| New Chemical Entity Exclusivity(NCE) | Jul 03, 2024 |
| Orphan Drug Exclusivity(ODE-257) | Jul 03, 2026 |
| Orphan Drug Exclusivity(ODE-310) | Jun 22, 2027 |
| ODE*(ODE*) | Dec 18, 2027 |
| Orphan Drug Exclusivity(ODE-346) | Dec 18, 2027 |
Drugs and Companies using SELINEXOR ingredient
NCE-1 date: 04 July, 2023
Market Authorisation Date: 10 March, 2025
Treatment: Xpovio is indicated for the treatment of adult patients with relapsed or refractory diffuse large b-cell lymphoma (dlbcl), not otherwise specified, including dlbcl arising from follicular lymphoma, af...
Dosage: TABLET
More Information on Dosage
XPOVIO family patents
47. Zerbaxa patent expiration
ZERBAXA's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7129232 | CUBIST PHARMS LLC | Cephem compounds |
May, 2028
(2 years from now) | |
| US8685957 | CUBIST PHARMS LLC | Tazobactam arginine compositions |
Sep, 2032
(7 years from now) | |
| US8476425 | CUBIST PHARMS LLC | Tazobactam arginine compositions |
Sep, 2032
(7 years from now) | |
| US8906898 | CUBIST PHARMS LLC | Solid forms of ceftolozane |
May, 2034
(9 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10028963 | CUBIST PHARMS LLC | Methods for treating intrapulmonary infections |
Sep, 2032
(7 years from now) | |
| US9724353 | CUBIST PHARMS LLC | Methods for treating intrapulmonary infections |
Sep, 2032
(7 years from now) | |
| US8968753 | CUBIST PHARMS LLC | Ceftolozane-tazobactam pharmaceutical compositions |
Mar, 2034
(8 years from now) | |
| US9320740 | CUBIST PHARMS LLC | Ceftolozane-tazobactam pharmaceutical compositions |
Mar, 2034
(8 years from now) | |
| US11278622 | CUBIST PHARMS LLC | Ceftolozane antibiotic compositions |
Mar, 2034
(8 years from now) | |
| US10420841 | CUBIST PHARMS LLC | Ceftolozane antibiotic compositions |
Mar, 2034
(8 years from now) | |
| US9872906 | CUBIST PHARMS LLC | Ceftolozane antibiotic compositions |
Mar, 2034
(8 years from now) | |
| US10933053 | CUBIST PHARMS LLC | Treating infections with ceftolozane/tazobactam in subjects having impaired renal function |
Sep, 2034
(9 years from now) | |
| US10376496 | CUBIST PHARMS LLC | Treating infections with ceftolozane/tazobactam in subjects having impaired renal function |
Sep, 2034
(9 years from now) | |
| US10125149 | CUBIST PHARMS LLC | Synthesis of cephalosporin compounds |
Aug, 2035
(10 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Dec 19, 2019 |
| Generating Antibiotic Incentives Now(GAIN) | Dec 19, 2024 |
| New Patient Population(NPP) | Apr 21, 2025 |
Drugs and Companies using CEFTOLOZANE SULFATE; TAZOBACTAM SODIUM ingredient
NCE-1 date: 20 December, 2023
Market Authorisation Date: 19 December, 2014
Treatment: Treatment of hospital-acquired bacterial pneumonia; Treatment of ventilator-associated bacterial pneumonia; Complicated intra-abdominal infections (ciai), used in combination with metronidazole, in ad...
Dosage: POWDER
More Information on Dosage
ZERBAXA family patents
48. Zulresso patent expiration
ZULRESSO's oppositions filed in EPO
Can you believe ZULRESSO received compensation for the extended wait time during the regulatory approval process?
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9750822 | SAGE THERAP | Sulfoalkyl ether cyclodextrin compositions |
Mar, 2029
(3 years from now) | |
| US7635773 | SAGE THERAP | Sulfoalkyl ether cyclodextrin compositions |
Mar, 2029
(3 years from now) | |
| US9200088 | SAGE THERAP | Sulfoalkyl ether cyclodextrin compositions |
Mar, 2029
(3 years from now) | |
| US8410077 | SAGE THERAP | Sulfoalkyl ether cyclodextrin compositions |
Mar, 2029
(3 years from now) | |
| US10117951 | SAGE THERAP | Sulfoalkyl ether cyclodextrin compositions |
Mar, 2029
(3 years from now) | |
| US10322139 | SAGE THERAP | Neuroactive steroid formulations and methods of treating CNS disorders |
Jan, 2033
(7 years from now) | |
| US10251894 | SAGE THERAP | Anticonvulsant activity of steroids |
Nov, 2033
(8 years from now) | |
| US10940156 | SAGE THERAP | Neuroactive steroids, compositions, and uses thereof |
Mar, 2037
(11 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jun 17, 2024 |
| New Patient Population(NPP) | Jun 16, 2025 |
Drugs and Companies using BREXANOLONE ingredient
NCE-1 date: 18 June, 2023
Market Authorisation Date: 17 June, 2019
Treatment: Method of treating postpartum depression
Dosage: SOLUTION
More Information on Dosage
ZULRESSO family patents